<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long‐acting beta2‐agonists (LABA) for adults with asthma - Kew, KM - 2015 | Cochrane Library</title> <meta content="Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long‐acting beta2‐agonists (LABA) for adults with asthma - Kew, KM - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011438.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long‐acting beta2‐agonists (LABA) for adults with asthma - Kew, KM - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011438.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011438.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long‐acting beta&lt;sub&gt;2&lt;/sub&gt;‐agonists (LABA) for adults with asthma" name="citation_title"/> <meta content="Kayleigh M Kew" name="citation_author"/> <meta content="BMJ" name="citation_author_institution"/> <meta content="kayleigh.m.kew@gmail.com" name="citation_author_email"/> <meta content="David JW Evans" name="citation_author"/> <meta content="Lancaster University" name="citation_author_institution"/> <meta content="Debbie E Anderson" name="citation_author"/> <meta content="University of Strathclyde" name="citation_author_institution"/> <meta content="Anne C Boyter" name="citation_author"/> <meta content="University of Strathclyde" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD011438.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/06/02" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011438.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011438.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011438.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Inhalation; Adrenal Cortex Hormones [*administration &amp; dosage]; Adrenergic beta‐2 Receptor Agonists [*administration &amp; dosage]; Asthma [*drug therapy]; Double‐Blind Method; Drug Therapy, Combination [methods]; Muscarinic Antagonists [*administration &amp; dosage]; Quality of Life; Randomized Controlled Trials as Topic; Salmeterol Xinafoate [administration &amp; dosage]; Tiotropium Bromide [administration &amp; dosage]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011438.pub2&amp;doi=10.1002/14651858.CD011438.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011438.pub2&amp;doi=10.1002/14651858.CD011438.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011438.pub2&amp;doi=10.1002/14651858.CD011438.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011438.pub2&amp;doi=10.1002/14651858.CD011438.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011438.pub2&amp;doi=10.1002/14651858.CD011438.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011438.pub2&amp;doi=10.1002/14651858.CD011438.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011438.pub2&amp;doi=10.1002/14651858.CD011438.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011438.pub2&amp;doi=10.1002/14651858.CD011438.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011438.pub2&amp;doi=10.1002/14651858.CD011438.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011438.pub2&amp;doi=10.1002/14651858.CD011438.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011438.pub2&amp;doi=10.1002/14651858.CD011438.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011438.pub2&amp;doi=10.1002/14651858.CD011438.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011438.pub2&amp;doi=10.1002/14651858.CD011438.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011438.pub2&amp;doi=10.1002/14651858.CD011438.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011438.pub2&amp;doi=10.1002/14651858.CD011438.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011438.pub2&amp;doi=10.1002/14651858.CD011438.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011438.pub2&amp;doi=10.1002/14651858.CD011438.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011438.pub2&amp;doi=10.1002/14651858.CD011438.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011438.pub2&amp;doi=10.1002/14651858.CD011438.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011438.pub2&amp;doi=10.1002/14651858.CD011438.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011438.pub2&amp;doi=10.1002/14651858.CD011438.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011438.pub2&amp;doi=10.1002/14651858.CD011438.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011438.pub2&amp;doi=10.1002/14651858.CD011438.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="VXKc2U6b";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011438\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011438\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011438\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011438\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","hr","fr","zh_HANS","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011438.pub2",title:"Long\\u2010acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long\\u2010acting beta\u003csub\u003e2\u003c/sub\u003e\\u2010agonists (LABA) for adults with asthma",firstPublishedDate:"Jun 2, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=VXKc2U6b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011438.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011438.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011438.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011438.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011438.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011438.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011438.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011438.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011438.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011438.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2821 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011438.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011438.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011438.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011438.pub2/full#CD011438-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011438.pub2/full#CD011438-sec-0105"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011438.pub2/full#CD011438-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011438.pub2/full#CD011438-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011438.pub2/full#CD011438-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011438.pub2/full#CD011438-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011438.pub2/full#CD011438-sec-0061"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011438.pub2/full#CD011438-sec-0099"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011438.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011438.pub2/appendices#CD011438-sec-0110"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011438.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011438.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/table_n/CD011438StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/table_n/CD011438StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011438.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011438.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011438.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011438.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011438.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011438.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long‐acting beta<sub>2</sub>‐agonists (LABA) for adults with asthma </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011438.pub2/information#CD011438-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Kayleigh M Kew</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011438.pub2/information#CD011438-cr-0003">David JW Evans</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011438.pub2/information#CD011438-cr-0004">Debbie E Anderson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011438.pub2/information#CD011438-cr-0005">Anne C Boyter</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/information/en#CD011438-sec-0121">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 02 June 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011438.pub2">https://doi.org/10.1002/14651858.CD011438.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011438-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011438-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011438-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011438-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011438-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011438-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011438-abs-0001" lang="en"> <section id="CD011438-sec-0001"> <h3 class="title" id="CD011438-sec-0001">Background</h3> <p>Poorly controlled asthma and preventable exacerbations place a significant strain on healthcare, often requiring additional medications, hospital stays or treatment in the emergency department. </p> <p>Long‐acting beta<sub>2</sub>‐agonists (LABA) are the preferred add‐on treatment for adults with asthma whose symptoms are not well controlled on inhaled corticosteroids (ICS), but have important safety concerns in asthma. Long‐acting muscarinic antagonists (LAMA) have confirmed efficacy in chronic obstructive pulmonary disease and are now being considered as an alternative add‐on therapy for people with uncontrolled asthma. </p> </section> <section id="CD011438-sec-0002"> <h3 class="title" id="CD011438-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of adding a LAMA to ICS compared with adding a LABA for adults whose asthma is not well controlled on ICS alone. </p> </section> <section id="CD011438-sec-0003"> <h3 class="title" id="CD011438-sec-0003">Search methods</h3> <p>We searched the Cochrane Airways Group's Specialised Register (CAGR) from inception to April 2015, and imposed no restriction on language of publication. We searched additional resources to pick up unpublished studies, including ClinicalTrials.gov, World Health Organization trials portal, reference lists of primary studies and existing reviews, and manufacturers' trial registries. The most recent search was conducted in April 2015. </p> </section> <section id="CD011438-sec-0004"> <h3 class="title" id="CD011438-sec-0004">Selection criteria</h3> <p>We searched for parallel and cross‐over RCTs in which adults whose asthma was not well controlled with ICS alone were randomised to receive LAMA add‐on or LABA add‐on for at least 12 weeks. </p> </section> <section id="CD011438-sec-0005"> <h3 class="title" id="CD011438-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened the electronic and additional searches and extracted data from study reports. We used Covidence for duplicate screening, extraction of study characteristics and numerical data, and risk of bias ratings. </p> <p>The pre‐specified primary outcomes were exacerbations requiring oral corticosteroids (OCS), quality of life and serious adverse events. </p> </section> <section id="CD011438-sec-0006"> <h3 class="title" id="CD011438-sec-0006">Main results</h3> <p>We included eight studies meeting the inclusion criteria, but four double‐blind, double‐dummy studies of around 2000 people dominated the analyses. These four trials were between 14 and 24 weeks long, all comparing tiotropium (usually Respimat) with salmeterol on top of medium doses of ICS. </p> <p>Studies reporting exacerbations requiring OCS showed no difference between the two add‐ons, but our confidence in the effect was low due to inconsistency between studies and because the confidence intervals (CI) included significant benefit of either treatment (odds ratio (OR) 1.05, 95% CI 0.50 to 2.18; 1753 participants; 3 studies); three more people per 1000 might have an exacerbation on LAMA, but the CIs ranged from 29 fewer to 61 more. Imprecision was also an issue for serious adverse events and exacerbations requiring hospital admission, rated low (serious adverse events) and very low quality (exacerbations requiring hospital admission), because there were so few events in the analyses. </p> <p>People taking LAMA scored slightly worse on two scales measuring quality of life (Asthma Quality of Life Questionnaire; AQLQ) and asthma control (Asthma Control Questionnaire; ACQ); the evidence was rated high quality but the effects were small and unlikely to be clinically significant (AQLQ: mean difference (MD) ‐0.12, 95% CI ‐0.18 to ‐0.05; 1745 participants; 1745; 4 studies; ACQ: MD 0.06, 95% CI 0.00 to 0.13; 1483 participants; 3 studies). </p> <p>There was some evidence to support small benefits of LAMA over LABA on lung function, including on our pre‐specified preferred measure trough forced expiratory volume in one second (FEV<sub>1</sub>) (MD 0.05 L, 95% CI 0.01 to 0.09; 1745 participants, 4 studies). However, the effects on other measures varied, and it is not clear whether the magnitude of the differences were clinically significant. </p> <p>More people had adverse events on LAMA but the difference with LABA was not statistically significant. </p> </section> <section id="CD011438-sec-0007"> <h3 class="title" id="CD011438-sec-0007">Authors' conclusions</h3> <p>Direct evidence of LAMA versus LABA as add‐on therapy is currently limited to studies of less than six months comparing tiotropium (Respimat) to salmeterol, and we do not know how they compare in terms of exacerbations and serious adverse events. There was moderate quality evidence that LAMAs show small benefits over LABA on some measures of lung function, and high quality evidence that LABAs are slightly better for quality of life, but the differences were all small. Given the much larger evidence base for LABA versus placebo for people whose asthma is not well controlled on ICS, the current evidence is not strong enough to say that LAMA can be substituted for LABA as add‐on therapy. </p> <p>The results of this review, alongside pending results from related reviews assessing the use of LAMA in other clinical scenarios, will help to define the role of these drugs in asthma and it is important that they be updated as results from ongoing and planned trials emerge. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011438-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011438-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011438-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011438-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011438-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011438-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011438-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011438-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011438-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011438-abs-0004" lang="en"> <h3>Is it better to add long‐acting muscarinic antagonists or long‐acting beta2‐agonists to inhaled corticosteroids for people with uncontrolled asthma? </h3> <p><b>Main point</b> </p> <p>Differences between long‐acting muscarinic antagonists (LAMA) and long‐acting beta<sub>2</sub>‐agonists (LABA) are mostly small or uncertain, based on studies less than six months in duration. The current evidence is not strong enough to support using LAMA instead of LABA for people whose asthma is not controlled on inhaled corticosteroids. </p> <p><b>Why is the question important?</b> </p> <p>People who have asthma that is not well controlled often have attacks that require extra treatment and time in hospital. </p> <p>LABA are inhaled drugs that can improve symptoms and reduce the likelihood of asthma attacks when inhaled corticosteroids are not helpful alone, but they can have serious side effects. LAMA, another type of inhaled drug that is already used for other lung diseases, are a possible new treatment option for this group of people with asthma. </p> <p><b>How did we answer the question?</b> </p> <p>We looked for randomised controlled studies (clinical studies where people are randomly put into one of two or more treatment groups) that compared LAMA with LABA, both on top of inhaled corticosteroids, for at least 12 weeks. Two people looked through all of the possible published and unpublished studies that we found from several databases and websites, to find a list of studies that looked at the question we were interested in. The most recent searches were done in April 2015. </p> <p><b>What did we find out?</b> </p> <p>We could not tell whether people taking LAMA were more or less likely to need oral corticosteroids for an asthma attack than people taking LABA because not many people needed them and the studies showed different results; overall three more people in 1000 might have an asthma attack on LAMA, but the real result could be anywhere between 29 fewer and 61 more than if you took a LABA. Similarly, too few people in the studies had serious side effects or asthma attacks that required urgent medical treatment to judge whether one treatment was better than the other. </p> <p>The studies showed that LAMAs might be a bit better than LABA for lung function (how well your lungs work), and LABAs slightly better for quality of life, but the differences were small and we could not tell if one was better than the other for most outcomes. </p> <p>The results were mostly based on four good studies of around 2000 people, which were between 14 and 24 weeks of duration. All of the studies looked at a LAMA drug called tiotropium. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011438-sec-0105" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011438-sec-0105"></div> <h3 class="title" id="CD011438-sec-0106">Implications for practice</h3> <section id="CD011438-sec-0106"> <p>Direct evidence of long‐acting muscarinic antagonists (LAMA) versus long‐acting beta<sub>2</sub>‐agonists (LABA) as add‐on therapy is currently limited to studies of less than six months comparing tiotropium Respimat to salmeterol, and we do not know how they compare in terms of exacerbations and serious adverse events. There is moderate quality evidence that LAMAs show small benefits over LABA on some measures of lung function, and high quality evidence that LABAs are slightly better for quality of life, but the differences were all small. Given the much larger evidence base for LABA versus placebo for people whose asthma is not well controlled on ICS, the current evidence is not strong enough to say that LAMA can be substituted for LABA as add‐on therapy. </p> </section> <h3 class="title" id="CD011438-sec-0107">Implications for research</h3> <section id="CD011438-sec-0107"> <p>The results of this review, alongside pending results from related reviews assessing the use of LAMA in other clinical scenarios, will help to define the role of these drugs in asthma and should be updated as results from known ongoing trials emerge. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011438-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011438-sec-0029"></div> <div class="table" id="CD011438-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Long‐acting muscarinic antagonists (LAMA) add‐on compared with long‐acting beta2‐agonists (LABA) add‐on for adults with asthma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Long‐acting muscarinic antagonists (LAMA) add‐on compared with long‐acting beta<sub>2</sub>‐agonists (LABA) add‐on for adults with asthma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with asthma not well controlled on ICS<br/> <b>Settings:</b> outpatient<br/> <b>Intervention:</b> LAMA add‐on<br/> <b>Comparison:</b> LABA add‐on </p> <p><b>Time point:</b> calculated as the mean duration of the studies contributing to each analysis </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk<sup>3</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>LABA add‐on</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>LAMA add‐on</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbations</b> (OCS) </p> <p>23 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>59 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1000<br/> (30 to 120) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.05</b><br/> (0.50 to 2.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1755<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No clear benefit of 1 add‐on over the other</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AQLQ total</b><br/> 1 = severely impaired; </p> <p>7 = not impaired at all</p> <p>22 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean score in the LABA group was 5.60</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean score in the LAMA group was 0.12 worse<br/> (0.18 worse to 0.05 worse) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1745<br/> (4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small LABA benefit;</p> <p>MCID = 0.5 so difference was unlikely to be clinically significant</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>22 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000<br/> (10 to 42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.84</b><br/> (0.41 to 1.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2012<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low <sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No clear benefit of 1 add‐on over the other</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbations (hospital)</b> </p> <p>22 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/> (1 to 23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.72</b><br/> (0.18 to 2.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2022<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low <sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No clear benefit of 1 add‐on over the other</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trough FEV<sub>1</sub> (L)</b><sup>6</sup> </p> <p>(higher is better)</p> <p>22 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean trough FEV<sub>1</sub> in the LABA group was 0.07 L </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean trough FEV<sub>1</sub> in the LAMA group was 0.05 L better (0.01 better to 0.09 better) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1745<br/> (4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> Moderate <sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small LAMA benefit</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ACQ total</b> </p> <p>0 = no impairment; 6 = maximum impairment</p> <p>23 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean score in the LABA group was 1.31</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean score in the LAMA group was 0.06 higher<br/> (0 higher to 0.12 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1483<br/> (3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small LABA benefit;</p> <p>MCID = 0.5 so difference was unlikely to be clinically significant</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (all)</b> </p> <p>23 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>519 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>544 per 1000<br/> (498 to 592) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.11</b><br/> (0.92 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1839<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>More people on LAMA had an adverse event but the difference with LABA was not statistically significant </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ACQ:</b> Asthma Control Questionnaire; <b>AQLQ:</b> Asthma Quality of Life Questionnaire; <b>CI: c</b> onfidence interval; <b>FEV<sub>1</sub>:</b> forced expiratory volume in 1 second; <b>ICS:</b> inhaled corticosteroid; <b>LABA:</b> long‐acting beta<sub>2</sub>‐agonist; <b>LAMA:</b> long‐acting muscarinic antagonist; <b>MCID:</b> minimal clinically important difference; <b>OCS:</b> oral corticosteroids; <b>OR:</b> odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Confidence intervals include important benefit on either treatment (‐1 imprecision). </p> <p><sup>2</sup> I<sup>2</sup> = 50%, which was not statistically significant (P value = 0.16), but visual inspection of the forest plot showed opposite directions of effect of the pooled twin trials and the cross‐over study (‐1 inconsistency) </p> <p><sup>3</sup> For continuous outcomes, the assumed risk was calculated as a weighted mean of the control group scores (<a href="./references#CD011438-bbs2-0002" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). clinicaltrials.gov/show/NCT00565266 (accessed 14 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">NCT00565266</a> not included in the AQLQ or ACQ calculation because the study reported change from baseline and the remaining studies reported endpoint data). For dichotomous outcomes, it was the pooled control group event rate of all included studies. </p> <p><sup>4</sup> There was some statistical heterogeneity in these outcomes (exacerbations requiring hospital admission: I<sup>2</sup> = 20%, P value = 0.29; trough FEV<sub>1</sub>: I<sup>2</sup> = 46%, P value = 0.14), which was not statistically significant, but visual inspection of the forest plots showed clear variation in study results (‐1 inconsistency). </p> <p><sup>5</sup> Very wide confidence intervals; small number of events in the analysis (‐2 imprecision). </p> <p><sup>6</sup> Other lung function outcomes showed mixed results: small benefit of LAMA on trough PEF (moderate quality), possible but non‐significant benefit of LAMA on peak FEV<sub>1</sub> (very low quality) and trough FVC (moderate quality), no effect on peak FVC (moderate quality), LABA benefit on percentage predicted FEV<sub>1</sub> (very low quality). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011438-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011438-sec-0030"></div> <section id="CD011438-sec-0031"> <h3 class="title" id="CD011438-sec-0031">Description of the condition</h3> <p>Asthma is a common and potentially serious chronic disease of the airways, which causes difficulty breathing due to narrowing of the airways, thickening of the airway walls and increased mucous production (<a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=z1407241532023984189675486111895%26versionPK1=z1410231223031559700511775421172%26versionPK2=z1410241155360694374969188734632#REF-GINA-2014" target="_blank">GINA 2014</a>). Asthma is recognised as a heterogeneous disease, but commonly causes symptoms including wheezing, shortness of breath, chest tightness and cough that vary over time in their occurrence, frequency and intensity (<a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=z1407241532023984189675486111895%26versionPK1=z1410231223031559700511775421172%26versionPK2=z1410241155360694374969188734632#REF-GINA-2014" target="_blank">GINA 2014</a>). </p> <p>Around the world and particularly in low‐ and middle‐income countries, asthma is frequently undiagnosed and untreated (<a href="./references#CD011438-bbs2-0052" title="International Union Against Tuberculosis and Lung Disease. The Global Asthma Report 2011. theunion.org/what‐we‐do/publications/technical/global‐asthma‐report (accessed 1 September 2014). ">Global Asthma Report 2011</a>), and remains a significant cause of avoidable morbidity and mortality in high‐income countries such as the UK (<a href="./references#CD011438-bbs2-0039" title="British Thoracic Society/Scottish Intercollegiate Guidelines Network. BTS/SIGN British guideline on the management of asthma, October 2014. www.brit‐thoracic.org.uk/guidelines‐and‐quality‐standards/asthma‐guideline/ (accessed 16 February 2015). ">BTS/SIGN 2014</a>; <a href="./references#CD011438-bbs2-0067" title="Royal College of Physicians. Why asthma still kills: the national review of asthma deaths. www.rcplondon.ac.uk/sites/default/files/why‐asthma‐still‐kills‐full‐report.pdf (accessed 1 September 2014). ">NRAD 2014</a>), imposing "a substantial burden on patients, their family and the community" (<a href="./references#CD011438-bbs2-0051" title="Global Initiative forAsthma . From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2014. www.ginasthma.org/ (accessed 29 August 2014). ">GINA 2014</a>). World Health Organization estimates suggest 300 million people are affected worldwide, with direct treatment costs and indirect costs of lost productivity among the highest for non‐communicable diseases (<a href="./references#CD011438-bbs2-0052" title="International Union Against Tuberculosis and Lung Disease. The Global Asthma Report 2011. theunion.org/what‐we‐do/publications/technical/global‐asthma‐report (accessed 1 September 2014). ">Global Asthma Report 2011</a>). Prevalence estimates vary, and changes over time have been linked to various factors including air pollution, tobacco legislation, diet and prevalence of other atopic diseases (<a href="./references#CD011438-bbs2-0034" title="AndersonHR . Prevalence of asthma. BMJ2005;330:1037. ">Anderson 2005</a>). </p> <p>The two broad aims of asthma treatment are to maintain daily symptom control and prevent acute worsening of symptoms known as asthma attacks or exacerbations. To achieve this, medication, usually given via an inhaler, is started at the most appropriate level based on the severity and frequency of symptoms according to treatment steps laid out in guidelines (e.g. <a href="./references#CD011438-bbs2-0051" title="Global Initiative forAsthma . From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2014. www.ginasthma.org/ (accessed 29 August 2014). ">GINA 2014</a>). Depending on symptom control and frequency of exacerbations when treatment has been commenced, therapy can be stepped up by increasing dose or adding medications to recapture control, or stepped down to maintain people at the lowest effective therapy and minimise adverse effects. </p> </section> <section id="CD011438-sec-0032"> <h3 class="title" id="CD011438-sec-0032">Description of the intervention</h3> <p>The lowest treatment step in most guidelines is the sole use of a short‐acting bronchodilating inhaler on an as‐needed basis (e.g. salbutamol), which is often sufficient to treat mild or intermittent asthma symptoms. Regular use of low‐dose inhaled corticosteroids (ICS) is the primary recommended preventer therapy for people with persistent asthma who remain inadequately controlled on as‐needed medication alone (<a href="./references#CD011438-bbs2-0039" title="British Thoracic Society/Scottish Intercollegiate Guidelines Network. BTS/SIGN British guideline on the management of asthma, October 2014. www.brit‐thoracic.org.uk/guidelines‐and‐quality‐standards/asthma‐guideline/ (accessed 16 February 2015). ">BTS/SIGN 2014</a>; <a href="./references#CD011438-bbs2-0051" title="Global Initiative forAsthma . From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2014. www.ginasthma.org/ (accessed 29 August 2014). ">GINA 2014</a>). Regular ICS improves lung function and reduces the need for reliever medications (<a href="./references#CD011438-bbs2-0031" title="AdamsNP , BestallJB , MaloufR , LassersonTJ , JonesPW . Beclomethasone versus placebo for chronic asthma. Cochrane Database of Systematic Reviews2008, Issue 4. [DOI: 10.1002/14651858.CD002738.pub2] ">Adams 2008a</a>; <a href="./references#CD011438-bbs2-0032" title="AdamsNP , BestallJC , LassersonTJ , JonesP , CatesCJ . Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2008, Issue 4. [DOI: 10.1002/14651858.CD003135.pub4] ">Adams 2008b</a>). However, some people with asthma will continue to have symptoms and asthma attacks on ICS alone and guidelines suggest a range of treatment options for this group of people (<a href="./references#CD011438-bbs2-0051" title="Global Initiative forAsthma . From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2014. www.ginasthma.org/ (accessed 29 August 2014). ">GINA 2014</a> step three and above). Long‐acting beta‐agonists (LABA), such as formoterol and salmeterol, are the current preferred add‐on therapy (<a href="./references#CD011438-bbs2-0039" title="British Thoracic Society/Scottish Intercollegiate Guidelines Network. BTS/SIGN British guideline on the management of asthma, October 2014. www.brit‐thoracic.org.uk/guidelines‐and‐quality‐standards/asthma‐guideline/ (accessed 16 February 2015). ">BTS/SIGN 2014</a>; <a href="./references#CD011438-bbs2-0045" title="DucharmeFM , Ni ChroininM , GreenstoneI , LassersonTJ . Addition of long‐acting beta2‐agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2008, Issue 5. [DOI: 10.1002/14651858.CD005535.pub2] ">Ducharme 2008</a>; <a href="./references#CD011438-bbs2-0051" title="Global Initiative forAsthma . From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2014. www.ginasthma.org/ (accessed 29 August 2014). ">GINA 2014</a>), as they have often small but statistically significant benefits on a range of outcomes over other treatment options such as increasing ICS dose (<a href="./references#CD011438-bbs2-0046" title="DucharmeFM , Ni ChoininM , GreenstoneI , LassersonTJ . Addition of long‐acting beta2‐agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database of Systematic Reviews2010, Issue 4. [DOI: 10.1002/14651858.CD005533.pub2] ">Ducharme 2010</a>), adding theophylline (<a href="./references#CD011438-bbs2-0072" title="TeeA , KohMS , GibsonPG , LassersonTJ , WilsonA , IrvingLB . Long‐acting beta2‐agonists versus theophylline for maintenance treatment of asthma. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD001281.pub2] ">Tee 2009</a>), or adding a leukotriene receptor antagonist (<a href="./references#CD011438-bbs2-0042" title="ChauhanBF , DucharmeFM . Addition to inhaled corticosteroids of long‐acting beta2‐agonists versus anti‐leukotrienes for chronic asthma. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD003137.pub5] ">Chauhan 2014</a>). Despite these confirmed benefits, LABA have been linked to increased morbidity and mortality in asthma (<a href="./references#CD011438-bbs2-0041" title="CatesCJ , WielandLS , OleszczukM , KewKM . Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD010314.pub2] ">Cates 2014</a>; <a href="./references#CD011438-bbs2-0064" title="NelsonHS , WeissST , BleeckerER , YanceySW , DorinskyPM , SMART Study Group. The salmeterol multicenter asthma research trial. Chest2006;129:15‐26. ">Nelson 2006</a>; <a href="./references#CD011438-bbs2-0071" title="SalpeterSR , BuckleyNS , OrmistonTM , SalpeterEE . Meta‐analysis: effect of long‐acting beta‐agonists on severe asthma exacerbations and asthma related deaths. Annals of Internal Medicine2006;144:904‐12. ">Salpeter 2006</a>), leading to warnings from the US Food and Drug Administration and the UK Medicines and Healthcare Products Regulatory Agency to highlight the increased risk of serious adverse events (<a href="./references#CD011438-bbs2-0050" title="United StatesFood , DrugAdministration . FDA Drug Safety Communication: New safety requirements for long‐acting inhaled asthma medications called long‐acting beta‐agonists (LABAs). www.fda.gov/drugs/drugsafety/ (accessed 29 August 2014). ">FDA 2010</a>; <a href="./references#CD011438-bbs2-0062" title="Medicines and Healthcare Products Regulatory Agency. Asthma long‐acting ß2 agonists: use and safety. www.gov.uk/government/publications/asthma‐long‐acting‐ss2‐agonists‐use‐and‐safety (accessed 16 February 2015). ">MHRA 2014</a>). While the risks are reduced when LABA are used as an add‐on treatment to ICS (<a href="./references#CD011438-bbs2-0041" title="CatesCJ , WielandLS , OleszczukM , KewKM . Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD010314.pub2] ">Cates 2014</a>; <a href="./references#CD011438-bbs2-0049" title="ErnstP , McIvorA , DucharmeFM , BouletLP , FitzgeraldM , ChapmanKR , et al. Safety and effectiveness of long‐acting inhaled beta‐agonist bronchodilators when taken with inhaled corticosteroids. Annals of Internal Medicine2006;146(9):692‐4. ">Ernst 2006</a>), it is still unclear whether the risk of adverse events remains higher than with ICS alone (<a href="./references#CD011438-bbs2-0045" title="DucharmeFM , Ni ChroininM , GreenstoneI , LassersonTJ . Addition of long‐acting beta2‐agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2008, Issue 5. [DOI: 10.1002/14651858.CD005535.pub2] ">Ducharme 2008</a>). </p> <p>ICS also carry risks and add‐on drugs that allow their dose to be kept low are often seen as preferable to high‐dose monotherapy. Prolonged use of higher doses of ICS carries the risk of serious unwanted effects including growth retardation in children, decreased bone density, eye disorders, sleep problems and anxiety (<a href="./references#CD011438-bbs2-0066" title="National Institute for Health and Care Excellence. NICE advice [KTT5] high‐dose inhaled corticosteroids in asthma. www.nice.org.uk/Advice/ktt5 (accessed 1 September 2014). ">NICE 2013</a>). </p> <p>Long‐acting muscarinic antagonists (LAMA), a class of drugs with confirmed effectiveness in chronic obstructive pulmonary disease (COPD) (<a href="./references#CD011438-bbs2-0055" title="KarnerC , ChongJ , PooleP . Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2014, Issue 7. [DOI: 10.1002/14651858.CD009285.pub3] ">Karner 2014</a>), are now being considered as an alternative to LABA add‐on therapy for adults with asthma requiring more than ICS alone. Tiotropium, the first LAMA to be licensed in COPD and the most widely used, has added benefits over LABA in terms of frequency of exacerbations and hospital admissions for COPD, but not in terms of mortality or overall hospital admissions (<a href="./references#CD011438-bbs2-0043" title="ChongJ , KarnerC , PooleP . Tiotropium versus long‐acting beta‐agonists for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD009157.pub2] ">Chong 2012</a>). Evidence for the safety and efficacy of aclidinium bromide and glycopyrronium bromide, two LAMA formulations that have been licensed for use in COPD, is emerging but less well established (<a href="./references#CD011438-bbs2-0065" title="NiH , SoeZ , MoeS . Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD010509.pub2] ">Ni 2014</a>). </p> </section> <section id="CD011438-sec-0033"> <h3 class="title" id="CD011438-sec-0033">How the intervention might work</h3> <p>LAMA block receptors of the neurotransmitter acetylcholine on airway smooth muscle, glands and nerves, preventing muscle contraction and mucous secretion (<a href="./references#CD011438-bbs2-0063" title="MoultonBC , FryerAD . Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD. British Journal of Clinical Pharmacology2011;163(1):44‐52. ">Moulton 2011</a>). The action on these receptors helps to alleviate symptoms of breathlessness, coughing and wheezing that characterise asthma (<a href="./references#CD011438-bbs2-0059" title="LipworthBJ . Emerging role of long acting muscarinic antagonists for asthma. British Journal of Clinical Pharmacology2014;77(1):55‐62. ">Lipworth 2014</a>). These characteristics of LAMA, and the overlap in pathophysiology and symptoms of asthma and COPD (<a href="./references#CD011438-bbs2-0053" title="GosensR , ZaagsmaJ , MeursH , HalaykoAJ . Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respiratory Research2006;7(1):73. ">Gosens 2006</a>), have led to their testing in asthma as an add‐on therapy for people who do not achieve adequate control from standard‐dose ICS alone, thus avoiding prolonged exposure to higher doses of ICS. </p> <p>The most commonly reported adverse effect of LAMA for airways disease is dry mouth, with others including constipation or diarrhoea, cough and headache (<a href="./references#CD011438-bbs2-0037" title="Joint Formulary Committee. British National Formulary. www.medicinescomplete.com (accessed 29 August 2014). ">BNF</a>). All LAMA for maintenance treatment of airways disease are delivered via inhalers, either by powder (HandiHaler, Genuair, Breezhaler) or soft mist delivery (Respimat), and are not suitable for use as rescue medication. </p> <p>In COPD, there is conflicting evidence regarding the safety of tiotropium delivered via the Respimat device, with one observational study finding it increases the risk of death, particularly from cardiac events, compared with both placebo and tiotropium via the HandiHaler device (<a href="./references#CD011438-bbs2-0074" title="VerhammeKM , AfonsoA , RomioS , StrickerBC , BrusselleGG , SturkenboomMC . Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD. European Respiratory Journal2013;42(3):606‐15. ">Verhamme 2013</a>). Another large randomised trial including over 17,000 people with COPD found no significant differences in long‐term safety between the two devices (<a href="./references#CD011438-bbs2-0075" title="WiseRA , AnzuetoA , CottonD , DahlR , DevinsT , DisseB , et al. Tiotropium Respimat Inhaler and the risk of death in COPD. New England Journal of Medicine2013;369:1491‐501. ">Wise 2013</a>). As yet, it is unclear whether differential safety profiles will be seen in people with asthma. </p> </section> <section id="CD011438-sec-0034"> <h3 class="title" id="CD011438-sec-0034">Why it is important to do this review</h3> <p>Only one preparation of LAMA (Spiriva Respimat 2.5 mcg) has been granted a UK license for use in severe asthma alongside LABA and ICS (<a href="./references#CD011438-bbs2-0048" title="Electronic MedicinesCompendium . License extension 19th September 2014: Spiriva Respimat 2.5 micrograms solution for inhalation. www.medicines.org.uk/emc/history/20134 (accessed 24 October 2014). ">eMC 2014</a>). Following its demonstrated efficacy in COPD (<a href="./references#CD011438-bbs2-0055" title="KarnerC , ChongJ , PooleP . Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2014, Issue 7. [DOI: 10.1002/14651858.CD009285.pub3] ">Karner 2014</a>), clinical trials are emerging testing various LAMA regimens against the existing treatment options. One study found that nearly 30% of people who were uncontrolled on fluticasone remained so with the guideline recommended addition of LABA (<a href="./references#CD011438-bbs2-0035" title="BatemanED , BousheyHA , BousquetJ , BusseWW , ClarkTJ , PauwelsRA , et al. Can guideline‐defined asthma control be achieved? The gaining optimal asthma control study. American Journal of Respiratory and Critical Care Medicine2004;170(8):836‐44. ">Bateman 2004</a>), suggesting there is a need for additional therapeutic options. Therefore, it is important to assess the efficacy and safety of LAMA add‐on against LABA add‐on, since LABA add‐on is the preferred step‐up treatment when ICS alone are ineffective (<a href="./references#CD011438-bbs2-0051" title="Global Initiative forAsthma . From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2014. www.ginasthma.org/ (accessed 29 August 2014). ">GINA 2014</a>). </p> <p>Three other reviews are currently being produced to assess 1. LAMA add‐on compared with increasing ICS dose (<a href="./references#CD011438-bbs2-0057" title="KewKM , AllisonDE , EvansDJW , BoyterAC . Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma. Cochrane Database of Systematic Reviews2014, Issue 12. [DOI: 10.1002/14651858.CD011437] ">Kew 2014</a>), 2. LAMA add‐on compared with no change to ICS dose (<a href="./references#CD011438-bbs2-0033" title="AllisonDE , KewKM , BoyterAC . Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS for adults with asthma. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD011397] ">Allison 2014</a>), and 3. LAMA add‐on as triple therapy with LABA plus ICS compared with LABA plus ICS alone (<a href="./references#CD011438-bbs2-0058" title="KewKM , DahriK . Long‐acting muscarinic antagonists (LAMA) added to combination long‐acting beta2‐agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database of Systematic Reviews2015, Issue 5. [DOI: 10.1002/14651858.CD011721] ">Kew 2015a</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011438-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011438-sec-0035"></div> <p>To assess the efficacy and safety of adding a LAMA to ICS compared with adding a LABA for adults whose asthma is not well controlled on ICS alone. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011438-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011438-sec-0036"></div> <section id="CD011438-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011438-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included parallel or cross‐over randomised controlled trials (RCTs) of at least 12 weeks' duration. We included studies reported as full‐text, abstract only and unpublished data. </p> <p>We did not exclude studies on the basis of blinding.</p> </section> <section id="CD011438-sec-0039"> <h4 class="title">Types of participants</h4> <p>We included adults (aged 18 years or older) whose asthma is not well controlled with ICS alone. We excluded trials that included participants with other chronic respiratory co‐morbidities (e.g. COPD, bronchiectasis). </p> <p>If studies included adults and adolescents or children under 12 and data were not reported separately, we included them if the mean age in both groups was over 18 years. </p> </section> <section id="CD011438-sec-0040"> <h4 class="title">Types of interventions</h4> <p>We included trials comparing the addition of LAMA add‐on with LABA add‐on to any dose of ICS. </p> <p>Studies involving the addition of the following LAMAs at any dose:</p> <p> <ul id="CD011438-list-0001"> <li> <p>tiotropium (Spiriva HandiHaler or Respimat);</p> </li> <li> <p>aclidinium bromide (Eklira Genuair);</p> </li> <li> <p>glycopyrronium bromide (Seebri Breezhaler).</p> </li> </ul> </p> <p>Eligible comparison groups were randomised to receive the same dose of ICS as the intervention group, with the addition of any of the following LABAs: </p> <p> <ul id="CD011438-list-0002"> <li> <p>formoterol 12 or 24 mcg twice daily</p> </li> <li> <p>salmeterol 50 mcg twice daily</p> </li> <li> <p>vilanterol 22 mcg once daily</p> </li> </ul> </p> <p>Since LABAs are available as single inhalers or in combination inhalers with ICS (e.g. Symbicort, Seretide, Dulera, Relvar), we included either formulation as long as the ICS was comparable to the dose given alongside the LAMA in the intervention group. </p> <p>We included studies that allowed participants to continue using their usual short‐ or long‐acting medications (e.g. salbutamol, terbutaline and ipratropium, leukotriene receptor antagonists), provided any non‐randomised LAMA or LABA were stopped during the study run‐in. </p> </section> <section id="CD011438-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD011438-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011438-list-0003"> <li> <p>Exacerbations requiring oral corticosteroids.</p> </li> <li> <p>Quality of life (measured on a validated asthma scale, e.g. Asthma Quality of Life Questionnaire; AQLQ). </p> </li> <li> <p>Any serious adverse event.</p> </li> </ul> </p> </section> <section id="CD011438-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011438-list-0004"> <li> <p>Exacerbations requiring hospitalisation.</p> </li> <li> <p>Lung function (in particular, trough forced expiratory volume in one second (FEV<sub>1</sub>)). </p> </li> <li> <p>Asthma control (measured on a validated scale, e.g. Asthma Control Questionnaire (ACQ) or Asthma Control Test). </p> </li> <li> <p>Any adverse events.</p> </li> </ul> </p> <p>Reporting one or more of the outcomes listed here in the trial was not an inclusion criterion for the review. </p> <p>If exacerbations were reported as a composite of more than one definition (e.g. people with one or more exacerbation requiring hospitalisation <i>or</i> emergency department visit), we analysed these separately. </p> </section> </section> </section> <section id="CD011438-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011438-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We identified trials from the Cochrane Airways Group's Specialised Register (CAGR), which is maintained by the Trials Search Co‐ordinator for the Group. The Register contains trial reports identified through systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED and PsycINFO, and handsearching of respiratory journals and meeting abstracts (see <a href="./appendices#CD011438-sec-0111">Appendix 1</a> for further details). We searched all records in the CAGR using the search strategy in <a href="./appendices#CD011438-sec-0117">Appendix 2</a>. </p> <p>We also conducted a search of ClinicalTrials.gov (<a href="http://www.ClinicalTrials.gov" target="_blank">www.ClinicalTrials.gov</a>), the World Health Organization (WHO) trials portal (<a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>) and industry trial registries. We searched all databases from their inception to April 2015, and we imposed no restriction on language of publication. Searches were conducted in April 2015. </p> </section> <section id="CD011438-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We checked reference lists of all primary studies and review articles for additional references. We searched relevant manufacturers' websites for trial information. </p> <p>We searched for errata or retractions from included studies published in full‐text on PubMed (<a href="http://www.ncbi.nlm.nih.gov/pubmed" target="_blank">www.ncbi.nlm.nih.gov/pubmed</a>) on 18 February 2015. </p> </section> </section> <section id="CD011438-sec-0047"> <h3 class="title" id="CD011438-sec-0047">Data collection and analysis</h3> <section id="CD011438-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Using <a href="./references#CD011438-bbs2-0044" title="The Alfred Hospital, Monash University, National ICT Australia and the University of London. Covidence. Version 1. Melbourne: Alfred Health, 2013. ">Covidence</a>, two review authors (KK and DE) independently screened titles and abstracts for inclusion of all the potential studies that we identified as a result of the search. We retrieved the full‐text study reports/publication and two review authors (KK and DE) independently screened the full text and identified studies for inclusion, and identified and recorded reasons for exclusion of the ineligible studies. We resolved any disagreement through discussion or, if required, we consulted a third review author (DA or AB). We identified and excluded duplicates and collated multiple reports of the same study so that each study, rather than each report, was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram and <a href="./references#CD011438-sec-0128" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD011438-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form in <a href="./references#CD011438-bbs2-0044" title="The Alfred Hospital, Monash University, National ICT Australia and the University of London. Covidence. Version 1. Melbourne: Alfred Health, 2013. ">Covidence</a> for study characteristics and outcome data, which was piloted on at least one study in the review. Two review authors (KK and DE) extracted study characteristics from included studies. We extracted the following study characteristics. </p> <p> <ul id="CD011438-list-0005"> <li> <p>Methods: study design, total duration of study, details of any 'run‐in' period, number of study centres and location, study setting, withdrawals and date of study. </p> </li> <li> <p>Participants: number, mean age, age range, gender, severity of condition, diagnostic criteria, baseline lung function, smoking history, inclusion criteria, and exclusion criteria. </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications and excluded medications.</p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, and time points reported. </p> </li> <li> <p>Notes: funding for trial, and notable conflicts of interest of trial authors.</p> </li> </ul> </p> <p>Two review authors (KK and DE) independently extracted outcome data from included studies. We noted in the <a href="./references#CD011438-sec-0127" title="">Characteristics of included studies</a> table if outcome data were not reported in a usable way. We resolved disagreements by consensus or by involving a third review author (DA or AB). One review author (KK) transferred data into Review Manager 5 (<a href="./references#CD011438-bbs2-0069" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We double‐checked that data were entered correctly by comparing the data presented in the systematic review with the study reports. A second review author (DE) spot‐checked study characteristics for accuracy against the trial reports. </p> </section> <section id="CD011438-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (KK and DE) independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011438-bbs2-0054" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We resolved any disagreements by discussion or by involving another review author (DA or AB). We assessed the risk of bias according to the following domains. </p> <p> <ul id="CD011438-list-0006"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias.</p> </li> </ul> </p> <p>We graded each potential source of bias as high, low or unclear and provided a quote from the study report together with a justification for our judgment in the 'Risk of bias' table. We summarised the risk of bias judgements across different studies for each of the domains listed. We considered blinding separately for different key outcomes where necessary (e.g. for unblinded outcome assessment, risk of bias for all‐cause mortality may be very different from a participant‐reported pain scale). Where information on risk of bias related to unpublished data or correspondence with a trialist, we noted this in the 'Risk of bias' table. </p> <p>When considering treatment effects, we took into account the risk of bias for the studies that contribute to that outcome. </p> <section id="CD011438-sec-0051"> <h5 class="title">Assessment of bias in conducting the systematic review</h5> <p>We conducted the review according to this published protocol and reported any deviations in the <a href="#CD011438-sec-0125">Differences between protocol and review</a> section of the systematic review. </p> </section> </section> <section id="CD011438-sec-0052"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data as odds ratios (OR) and continuous data as mean difference (MD) or standardised mean difference (SMD) with their 95% confidence intervals (CI). We entered data presented as a scale with a consistent direction of effect. We narratively described skewed data reported as medians and interquartile ranges. We analysed data from cross‐over trials using generic inverse variance (GIV) and only if double‐counting of participants has been accounted for. If raw data and adjusted analyses (e.g. accounting for baseline differences) were both presented, we used the adjusted analyses. When data published in peer‐reviewed papers was different to that given on clinicaltrials.gov, we cross‐checked them and contacted the study sponsor or trial author for more information if there was a discrepancy in the effect. </p> <p>We undertook meta‐analyses only where meaningful (i.e. if the treatments, participants and the underlying clinical question were similar enough for pooling to make sense). </p> <p>Where multiple trial arms were reported in a single trial, we included only the relevant arms. If two comparisons (e.g. drug A versus placebo and drug B versus placebo) were combined in the same meta‐analysis, we halved the control group to avoid double counting. </p> <p>If change from baseline and endpoint scores were available for continuous data, we used change from baseline unless the majority of studies reported endpoint scores. If a study reported outcomes at multiple time points, we used the end‐of‐study measurement. </p> <p>When an analysis using only participants who completed the trial and an analysis that imputed data for participants who were randomised but did not provide endpoint data (e.g. last observation carried forward) were both available, we used the analysis that imputed data. </p> <p>For dichotomous outcomes, we assumed equivalence of treatments if the OR estimate and its 95% CI were between the pre‐defined arbitrary limits of 0.9 and 1.1. </p> </section> <section id="CD011438-sec-0053"> <h4 class="title">Unit of analysis issues</h4> <p>For dichotomous outcomes, we used participants rather than events as the unit of analysis (i.e. number of adults admitted to hospital rather than number of admissions per adult). However, if exacerbations were reported as rate ratios we analysed them on this basis. For cross‐over trials, we requested data in the format shown in <a href="./appendices#CD011438-sec-0118">Appendix 3</a> for dichotomous outcomes in order to control for intercorrelation of matched pairs (<a href="./references#CD011438-bbs2-0047" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonH , ValeA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31:140‐9. ">Elbourne 2002</a>). For continuous data in cross‐over trials, we entered data using GIV from suitable adjusted analyses to account for the trial's design. </p> </section> <section id="CD011438-sec-0054"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors in order to verify key study characteristics and obtain missing numerical outcome data where possible (e.g. when a study was identified as abstract only). Where this was not possible, and the missing data were thought to introduce serious bias, we explored the impact of including such studies in the overall assessment of results using a sensitivity analysis<b>. </b> </p> </section> <section id="CD011438-sec-0055"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I<sup>2</sup> statistic to measure heterogeneity among the trials in each analysis. If we identified substantial heterogeneity (e.g. I<sup>2</sup> greater than 30%), we reported it and explored possible causes by pre‐specified subgroup analysis.  </p> </section> <section id="CD011438-sec-0056"> <h4 class="title">Assessment of reporting biases</h4> <p>We were not able to pool more than 10 trials, so were unable to examine a funnel plot to explore possible small‐study and publication biases. </p> </section> <section id="CD011438-sec-0057"> <h4 class="title">Data synthesis</h4> <p>We used a random‐effects model for all analyses as we expected variation in effects due to differences in study populations and methods. We performed sensitivity analyses using fixed‐effect. </p> <section id="CD011438-sec-0058"> <h5 class="title">'Summary of findings' table</h5> <p>We created a 'Summary of findings' table for all outcomes named in this protocol<i>.</i> We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of a body of evidence as it related to the studies that contributed data to the meta‐analyses for the pre‐specified outcomes. We used methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011438-bbs2-0054" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) using GRADEpro software (<a href="./references#CD011438-bbs2-0038" title="BrozekJ , OxmanA , SchünemannH . GRADEPro Version 3.2 for Windows. McMasters, Canada, 2008. ">Brozek 2008</a>). We justified all decisions to downgrade or upgrade the quality of studies using footnotes and we made comments to aid readers' understanding of the review where necessary. </p> </section> </section> <section id="CD011438-sec-0059"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned the following subgroup analyses for the primary outcomes, using the formal test for subgroup differences in Review Manager 5 (<a href="./references#CD011438-bbs2-0069" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>): </p> <p> <ul id="CD011438-list-0007"> <li> <p>Duration of therapy (six months or less, more than six months).</p> </li> <li> <p>Corticosteroid dose (according to <a href="http://archie.cochrane.org/sections/documents/view?document=z1405201158356969485713945219635%26format=REVMAN#REF-GINA-2014" target="_blank">GINA 2014</a> ‐ defined low, medium and high cut‐offs). </p> </li> <li> <p>Dose and type of LABA (e.g. formoterol 24 mcg, salmeterol 50 mcg).</p> </li> <li> <p>Dose and type of LAMA (e.g. tiotropium HandiHaler 18 mcg, tiotropium Respimat 5 mcg).</p> </li> </ul> </p> </section> <section id="CD011438-sec-0060"> <h4 class="title">Sensitivity analysis</h4> <p>We planned sensitivity analyses for the primary outcomes by excluding the following:</p> <p> <ul id="CD011438-list-0008"> <li> <p>studies at high risk of bias for blinding of participants and personnel;</p> </li> <li> <p>unpublished data (i.e. no peer‐reviewed full paper available);</p> </li> <li> <p>cross‐over trials.</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011438-sec-0061" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011438-sec-0061"></div> <section id="CD011438-sec-0062"> <h3 class="title">Description of studies</h3> <section id="CD011438-sec-0063"> <h4 class="title">Results of the search</h4> <p>We identified 76 records in the electronic database searches, and 121 additional records by searching clinicaltrials.gov, reference lists of other publications and drug company trial registries. We identified 54 of the total 197 as duplicates and screened titles and abstracts for the remaining 143. We excluded 104 at this stage. We retrieved full texts for the remaining 39, and we excluded 23 at this stage, which related to 19 excluded studies. The main reason for exclusion was the wrong comparator being used (11 publications), such as ICS alone (relevant to a separate review). Other reasons for exclusion were 'too short' (i.e. less than 12 weeks' duration) (six publications), wrong population (three) and wrong intervention (one). One study was not an RCT, and one was withdrawn prior to enrolment of participants. The remaining 16 citations related to eight studies, which were included in the qualitative synthesis. <a href="#CD011438-fig-0001">Figure 1</a> shows the trial flow. </p> <div class="figure" id="CD011438-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011438-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011438-sec-0064"> <h4 class="title">Included studies</h4> <p>Eight studies met all the inclusion criteria and were included in the review, but only four could be included in the quantitative synthesis. The four studies appearing in at least one meta‐analysis randomised 2049 people with asthma to the treatment arms compared in this review. One of the remaining four studies was terminated (<a href="./references#CD011438-bbs2-0003" title="NCT00706446 . Genotype stratified treatment with anticholinergic vs. beta‐agonist (long acting) and exacerbations (GABLE). clinicaltrials.gov/show/NCT00706446 (accessed 18 December 2014). ">NCT00706446</a>), one did not report any results on clinicaltrials.gov (<a href="./references#CD011438-bbs2-0006" title="NCT01290874 . Blacks and exacerbations on LABA vs. tiotropium (BELT). clinicaltrials.gov/show/NCT01290874 (accessed 18 December 2014). ">NCT01290874</a>), and the two others did not report data that could be pooled with the other studies (<a href="./references#CD011438-bbs2-0007" title="RajanandhMG , NageswariAD , IlangoK . Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxofylline, and tiotropium with budesonide: a randomized controlled study. Clinical Therapeutics2014;36(4):526‐33. ">Rajanandh 2014</a>; <a href="./references#CD011438-bbs2-0008" title="IlangoK . A clinical trial to study the effects of few anti asthmatic drug combinations on asthma patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2012/08/002915 (accessed 8 January 2015). RajanandhMG , NageswariAD , IlangoK . Assessment of montelukast, doxofylline, and tiotropium with budesonide for the treatment of asthma: which is the best among the second‐line treatment? A randomized trial. Clinical Therapeutics2015;37(2):41826. RajanandhMG , NageswariAD , IlangoK . Assessment of various second‐line medications in addition to inhaled corticosteroid in asthma patients: a randomized trial. Clinical and Experimental Pharmacology and Physiology2014;41(7):509‐13. ">Rajanandh 2015</a>). Data that could not be combined in meta‐analysis are described narratively in <a href="#CD011438-sec-0077">Effects of interventions</a>. Summary study characteristics including study duration and location, treatments received and blinding, are presented in <a href="#CD011438-tbl-0002">Table 1</a>. </p> <div class="table" id="CD011438-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary characteristics of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total number participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration (weeks)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Design</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ICS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Add‐ons</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean age (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% predicted FEV<sub>1</sub> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011438-bbs2-0001" title="BatemanED , KornmannO , SchmidtP , PivovarovaA , EngelM , FabbriLM . Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16‐Arg/Arg patients with asthma. Journal of Allergy and Clinical Immunology2011;128(2):315‐22. NCT00350207 . A 16‐week randomised, placebo‐controlled, double‐blind, double‐dummy, parallel‐group study comparing the efficacy and safety of tiotropium inhalation solution delivered by the Respimat Inhaler (2 actuations of 2.5 mcg once daily) with that of salmeterol from the hydrofluoroalkane metered dose inhaler (2 actuations of 25 mcg twice daily) in moderate persistent asthma patients with the B16‐Arg/Arg genotype. clinicaltrials.gov/show/NCT00350207 (accessed 18 December 2014). ">NCT00350207</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>International</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P, DB/DD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Budesonide 400‐1000 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Tio Respimat 5 mcg once daily</p> <p>2) Salmeterol 50 mcg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.5</p> <p>42.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.1</p> <p>75.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011438-bbs2-0002" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). clinicaltrials.gov/show/NCT00565266 (accessed 14 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">NCT00565266</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C, DB/DD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Beclomethasone dipropionate 80 mcg x2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Tio HandiHaler 18 mcg once daily</p> <p>2) Salmeterol 50 mcg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011438-bbs2-0003" title="NCT00706446 . Genotype stratified treatment with anticholinergic vs. beta‐agonist (long acting) and exacerbations (GABLE). clinicaltrials.gov/show/NCT00706446 (accessed 18 December 2014). ">NCT00706446</a> </p> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>355**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P, OL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Variable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Tiotropium (dose/ type NR)</p> <p>2) Salmeterol <i>or</i> formoterol (dose NR) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011438-bbs2-0004" title="NCT01172808 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® Inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 Weeks in moderate persistent asthma. clinicaltrials.gov/show/NCT01172808 (accessed 18 December 2014). ">NCT01172808</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>International</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>801</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P, DB/ DD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Continued stable, medium dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Tio Respimat 2.5 mcg once daily</p> <p>2) Tio Respimat 5 mcg once daily</p> <p>3) Salmeterol 50 mcg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.7</p> <p>44.4</p> <p>42.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011438-bbs2-0005" title="CasaleT , BleeckerE , MeltzerE , PizzichiniE , SchmidtO , BatemanE , et al. Phase III trials to investigate tiotropium as add‐on therapy to inhaled corticosteroids for patients with symptomatic asthma: trial design and planned statistical analyses. Allergy2013;68:377. CasaleTB , BatemanED , DahlR , PizzichiniE , VandewalkerML , VirchowJC , et al. Tiotropium Respimat (R) add‐on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of T(H)2 inflammatory status. Journal of Allergy and Clinical Immunology2014;133(2):Ab5. NCT01172821 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® Inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 Weeks in moderate persistent asthma. clinicaltrials.gov/show/NCT01172821 (accessed 18 December 2014). ">NCT01172821</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>International</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>776</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P, DB/DD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Continued stable, medium dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Tio Respimat 2.5 mcg once daily</p> <p>2) Tio Respimat 5 mcg once daily</p> <p>3) Salmeterol 50 mcg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.0</p> <p>44.3</p> <p>41.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011438-bbs2-0006" title="NCT01290874 . Blacks and exacerbations on LABA vs. tiotropium (BELT). clinicaltrials.gov/show/NCT01290874 (accessed 18 December 2014). ">NCT01290874</a> </p> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P, OL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Tio HandiHaler 18 mcg once daily</p> <p>2) Salmeterol 50 mcg <i>or</i> formoterol 12 mcg twice daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011438-bbs2-0007" title="RajanandhMG , NageswariAD , IlangoK . Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxofylline, and tiotropium with budesonide: a randomized controlled study. Clinical Therapeutics2014;36(4):526‐33. ">Rajanandh 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P, OL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Budesonide 400 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Tio HandiHaler 18 mcg once daily</p> <p>2) Formoterol 12 mcg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.4</p> <p>37.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.9</p> <p>66.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011438-bbs2-0008" title="IlangoK . A clinical trial to study the effects of few anti asthmatic drug combinations on asthma patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2012/08/002915 (accessed 8 January 2015). RajanandhMG , NageswariAD , IlangoK . Assessment of montelukast, doxofylline, and tiotropium with budesonide for the treatment of asthma: which is the best among the second‐line treatment? A randomized trial. Clinical Therapeutics2015;37(2):41826. RajanandhMG , NageswariAD , IlangoK . Assessment of various second‐line medications in addition to inhaled corticosteroid in asthma patients: a randomized trial. Clinical and Experimental Pharmacology and Physiology2014;41(7):509‐13. ">Rajanandh 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P, OL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Budesonide 400 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Tio HandiHaler 18 mcg once daily</p> <p>2) Formoterol 12 mcg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.4</p> <p>38.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.1</p> <p>66.2</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Total number participants is the number randomised to the groups of interest for this review. Age and % predicted FEV<sub>1</sub> are presented as mean values. </p> <p>C: cross‐over; DB/DD: double‐blind, double‐dummy; FEV<sub>1</sub>: forced expiratory volume in 1 second; ICS: inhaled corticosteroids; NR: not reported; OL: open label; P: parallel. </p> <p>* Cross‐over study so characteristics are for the whole population; every participant received each treatment for 14 weeks with a 2‐week washout period. </p> <p>** Planned enrolment and duration ‐ study was terminated.</p> </div> </div> <section id="CD011438-sec-0065"> <h5 class="title">Design and duration</h5> <p>All eight studies were RCTs of at least 12 weeks' duration. All but one of the studies had a parallel design, and the remaining was a three‐period cross‐over (<a href="./references#CD011438-bbs2-0002" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). clinicaltrials.gov/show/NCT00565266 (accessed 14 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">NCT00565266</a>). Three studies were international trials conducted at multiple sites across various countries (<a href="./references#CD011438-bbs2-0001" title="BatemanED , KornmannO , SchmidtP , PivovarovaA , EngelM , FabbriLM . Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16‐Arg/Arg patients with asthma. Journal of Allergy and Clinical Immunology2011;128(2):315‐22. NCT00350207 . A 16‐week randomised, placebo‐controlled, double‐blind, double‐dummy, parallel‐group study comparing the efficacy and safety of tiotropium inhalation solution delivered by the Respimat Inhaler (2 actuations of 2.5 mcg once daily) with that of salmeterol from the hydrofluoroalkane metered dose inhaler (2 actuations of 25 mcg twice daily) in moderate persistent asthma patients with the B16‐Arg/Arg genotype. clinicaltrials.gov/show/NCT00350207 (accessed 18 December 2014). ">NCT00350207</a>; <a href="./references#CD011438-bbs2-0004" title="NCT01172808 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® Inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 Weeks in moderate persistent asthma. clinicaltrials.gov/show/NCT01172808 (accessed 18 December 2014). ">NCT01172808</a>; <a href="./references#CD011438-bbs2-0005" title="CasaleT , BleeckerE , MeltzerE , PizzichiniE , SchmidtO , BatemanE , et al. Phase III trials to investigate tiotropium as add‐on therapy to inhaled corticosteroids for patients with symptomatic asthma: trial design and planned statistical analyses. Allergy2013;68:377. CasaleTB , BatemanED , DahlR , PizzichiniE , VandewalkerML , VirchowJC , et al. Tiotropium Respimat (R) add‐on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of T(H)2 inflammatory status. Journal of Allergy and Clinical Immunology2014;133(2):Ab5. NCT01172821 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® Inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 Weeks in moderate persistent asthma. clinicaltrials.gov/show/NCT01172821 (accessed 18 December 2014). ">NCT01172821</a>), three were conducted in the US (<a href="./references#CD011438-bbs2-0002" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). clinicaltrials.gov/show/NCT00565266 (accessed 14 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">NCT00565266</a>; <a href="./references#CD011438-bbs2-0003" title="NCT00706446 . Genotype stratified treatment with anticholinergic vs. beta‐agonist (long acting) and exacerbations (GABLE). clinicaltrials.gov/show/NCT00706446 (accessed 18 December 2014). ">NCT00706446</a>; <a href="./references#CD011438-bbs2-0006" title="NCT01290874 . Blacks and exacerbations on LABA vs. tiotropium (BELT). clinicaltrials.gov/show/NCT01290874 (accessed 18 December 2014). ">NCT01290874</a>), and two were conducted in India (<a href="./references#CD011438-bbs2-0007" title="RajanandhMG , NageswariAD , IlangoK . Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxofylline, and tiotropium with budesonide: a randomized controlled study. Clinical Therapeutics2014;36(4):526‐33. ">Rajanandh 2014</a>; <a href="./references#CD011438-bbs2-0008" title="IlangoK . A clinical trial to study the effects of few anti asthmatic drug combinations on asthma patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2012/08/002915 (accessed 8 January 2015). RajanandhMG , NageswariAD , IlangoK . Assessment of montelukast, doxofylline, and tiotropium with budesonide for the treatment of asthma: which is the best among the second‐line treatment? A randomized trial. Clinical Therapeutics2015;37(2):41826. RajanandhMG , NageswariAD , IlangoK . Assessment of various second‐line medications in addition to inhaled corticosteroid in asthma patients: a randomized trial. Clinical and Experimental Pharmacology and Physiology2014;41(7):509‐13. ">Rajanandh 2015</a>). Overall, six of the eight studies lasted six months or less. Two were one‐year long studies, but neither reported any data (<a href="./references#CD011438-bbs2-0003" title="NCT00706446 . Genotype stratified treatment with anticholinergic vs. beta‐agonist (long acting) and exacerbations (GABLE). clinicaltrials.gov/show/NCT00706446 (accessed 18 December 2014). ">NCT00706446</a>; <a href="./references#CD011438-bbs2-0006" title="NCT01290874 . Blacks and exacerbations on LABA vs. tiotropium (BELT). clinicaltrials.gov/show/NCT01290874 (accessed 18 December 2014). ">NCT01290874</a>). </p> <p>Four of the studies were double‐blind, double‐dummy designs, and four were open‐label; none of the open‐label studies contributed data to the meta‐analyses. </p> </section> <section id="CD011438-sec-0066"> <h5 class="title">Participant inclusion and exclusion criteria</h5> <p>All of the studies listed detailed inclusion and exclusion criteria within their published reports or on a trial registration website. All studies recruited men and women of at least 18 years of age, and some stipulated an upper age limit of 60 or 65 years. Other inclusion criteria that were common across studies included currently not smoking and a smoking history of less than 10 pack‐years, informed consent, contraception measures for women, and ability to use study devices and perform the necessary procedures. The diagnosis of asthma required across studies was defined differently, and sometimes only a 'clinical history' with no specific criteria stated. In general, though, reversibility to short‐acting beta<sub>2</sub>‐agonists (SABA), percentage predicted FEV<sub>1</sub> above 40% and the need for daily controller medication was required. One study recruited only black people (<a href="./references#CD011438-bbs2-0006" title="NCT01290874 . Blacks and exacerbations on LABA vs. tiotropium (BELT). clinicaltrials.gov/show/NCT01290874 (accessed 18 December 2014). ">NCT01290874</a>), and another study recruited people who were homozygous for arginine at the 16th amino acid position of the beta<sub>2</sub>‐adrenergic receptor (<a href="./references#CD011438-bbs2-0001" title="BatemanED , KornmannO , SchmidtP , PivovarovaA , EngelM , FabbriLM . Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16‐Arg/Arg patients with asthma. Journal of Allergy and Clinical Immunology2011;128(2):315‐22. NCT00350207 . A 16‐week randomised, placebo‐controlled, double‐blind, double‐dummy, parallel‐group study comparing the efficacy and safety of tiotropium inhalation solution delivered by the Respimat Inhaler (2 actuations of 2.5 mcg once daily) with that of salmeterol from the hydrofluoroalkane metered dose inhaler (2 actuations of 25 mcg twice daily) in moderate persistent asthma patients with the B16‐Arg/Arg genotype. clinicaltrials.gov/show/NCT00350207 (accessed 18 December 2014). ">NCT00350207</a>). </p> <p>Exclusion criteria that were common across studies included a range of other "significant" medical illnesses, often to be judged so by the study investigators (commonly including cancers, myocardial infarction, heart failure and arrhythmia). Also common were the exclusion of other lung diseases (commonly COPD, bronchiectasis, cystic fibrosis and tuberculosis), thoracotomy with pulmonary resection and current or recent participation in pulmonary rehabilitation. Studies also generally excluded participants with a recent respiratory tract infection or exacerbation of asthma (within four weeks), and people who had been classified as having life‐threatening asthma within five years of study entry. Pregnant or nursing women were generally excluded from participation, as were people with hypersensitivity or contraindications to any component of the study drugs, and people with current prior alcohol or drug misuse. Exclusion due to the use of other asthma medications were varied, but generally participants were not included if they were taking, or had recently taken, other long‐acting medications or drugs given to people with very severe asthma (e.g. OCS), and anti‐immunoglobulin (Ig)E medications such as omalizumab. </p> </section> <section id="CD011438-sec-0067"> <h5 class="title">Participant baseline characteristics</h5> <p>Baseline characteristics, with the exception of percentage male and mean age, were generally poorly reported across studies. Mean percentage predicted FEV<sub>1</sub> at baseline was between 66% and 76% in the three studies reporting it (<a href="./references#CD011438-bbs2-0001" title="BatemanED , KornmannO , SchmidtP , PivovarovaA , EngelM , FabbriLM . Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16‐Arg/Arg patients with asthma. Journal of Allergy and Clinical Immunology2011;128(2):315‐22. NCT00350207 . A 16‐week randomised, placebo‐controlled, double‐blind, double‐dummy, parallel‐group study comparing the efficacy and safety of tiotropium inhalation solution delivered by the Respimat Inhaler (2 actuations of 2.5 mcg once daily) with that of salmeterol from the hydrofluoroalkane metered dose inhaler (2 actuations of 25 mcg twice daily) in moderate persistent asthma patients with the B16‐Arg/Arg genotype. clinicaltrials.gov/show/NCT00350207 (accessed 18 December 2014). ">NCT00350207</a>; <a href="./references#CD011438-bbs2-0002" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). clinicaltrials.gov/show/NCT00565266 (accessed 14 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">NCT00565266</a>; <a href="./references#CD011438-bbs2-0007" title="RajanandhMG , NageswariAD , IlangoK . Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxofylline, and tiotropium with budesonide: a randomized controlled study. Clinical Therapeutics2014;36(4):526‐33. ">Rajanandh 2014</a>; <a href="./references#CD011438-bbs2-0008" title="IlangoK . A clinical trial to study the effects of few anti asthmatic drug combinations on asthma patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2012/08/002915 (accessed 8 January 2015). RajanandhMG , NageswariAD , IlangoK . Assessment of montelukast, doxofylline, and tiotropium with budesonide for the treatment of asthma: which is the best among the second‐line treatment? A randomized trial. Clinical Therapeutics2015;37(2):41826. RajanandhMG , NageswariAD , IlangoK . Assessment of various second‐line medications in addition to inhaled corticosteroid in asthma patients: a randomized trial. Clinical and Experimental Pharmacology and Physiology2014;41(7):509‐13. ">Rajanandh 2015</a>). Mean ages were all between 37 and 45 years. The proportion of men and women was fairly balanced within studies reporting this information, and across studies the percentage of men ranged between 33% (<a href="./references#CD011438-bbs2-0002" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). clinicaltrials.gov/show/NCT00565266 (accessed 14 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">NCT00565266</a>) and 65% (LAMA group of <a href="./references#CD011438-bbs2-0007" title="RajanandhMG , NageswariAD , IlangoK . Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxofylline, and tiotropium with budesonide: a randomized controlled study. Clinical Therapeutics2014;36(4):526‐33. ">Rajanandh 2014</a>). </p> </section> <section id="CD011438-sec-0068"> <h5 class="title">Characteristics of the interventions</h5> <p>All of the studies compared the LAMA, tiotropium, to salmeterol or formoterol, both used as an add‐on drug to ICS. <a href="./references#CD011438-bbs2-0004" title="NCT01172808 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® Inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 Weeks in moderate persistent asthma. clinicaltrials.gov/show/NCT01172808 (accessed 18 December 2014). ">NCT01172808</a> and <a href="./references#CD011438-bbs2-0005" title="CasaleT , BleeckerE , MeltzerE , PizzichiniE , SchmidtO , BatemanE , et al. Phase III trials to investigate tiotropium as add‐on therapy to inhaled corticosteroids for patients with symptomatic asthma: trial design and planned statistical analyses. Allergy2013;68:377. CasaleTB , BatemanED , DahlR , PizzichiniE , VandewalkerML , VirchowJC , et al. Tiotropium Respimat (R) add‐on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of T(H)2 inflammatory status. Journal of Allergy and Clinical Immunology2014;133(2):Ab5. NCT01172821 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® Inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 Weeks in moderate persistent asthma. clinicaltrials.gov/show/NCT01172821 (accessed 18 December 2014). ">NCT01172821</a> were multi‐arm twin trials that included separate arms for two doses of tiotropium Respimat, 2.5 mcg daily and 5 mcg daily. <a href="./references#CD011438-bbs2-0001" title="BatemanED , KornmannO , SchmidtP , PivovarovaA , EngelM , FabbriLM . Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16‐Arg/Arg patients with asthma. Journal of Allergy and Clinical Immunology2011;128(2):315‐22. NCT00350207 . A 16‐week randomised, placebo‐controlled, double‐blind, double‐dummy, parallel‐group study comparing the efficacy and safety of tiotropium inhalation solution delivered by the Respimat Inhaler (2 actuations of 2.5 mcg once daily) with that of salmeterol from the hydrofluoroalkane metered dose inhaler (2 actuations of 25 mcg twice daily) in moderate persistent asthma patients with the B16‐Arg/Arg genotype. clinicaltrials.gov/show/NCT00350207 (accessed 18 December 2014). ">NCT00350207</a> used tiotropium at 5 mcg daily; <a href="./references#CD011438-bbs2-0002" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). clinicaltrials.gov/show/NCT00565266 (accessed 14 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">NCT00565266</a>, <a href="./references#CD011438-bbs2-0006" title="NCT01290874 . Blacks and exacerbations on LABA vs. tiotropium (BELT). clinicaltrials.gov/show/NCT01290874 (accessed 18 December 2014). ">NCT01290874</a>, <a href="./references#CD011438-bbs2-0007" title="RajanandhMG , NageswariAD , IlangoK . Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxofylline, and tiotropium with budesonide: a randomized controlled study. Clinical Therapeutics2014;36(4):526‐33. ">Rajanandh 2014</a>, and <a href="./references#CD011438-bbs2-0008" title="IlangoK . A clinical trial to study the effects of few anti asthmatic drug combinations on asthma patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2012/08/002915 (accessed 8 January 2015). RajanandhMG , NageswariAD , IlangoK . Assessment of montelukast, doxofylline, and tiotropium with budesonide for the treatment of asthma: which is the best among the second‐line treatment? A randomized trial. Clinical Therapeutics2015;37(2):41826. RajanandhMG , NageswariAD , IlangoK . Assessment of various second‐line medications in addition to inhaled corticosteroid in asthma patients: a randomized trial. Clinical and Experimental Pharmacology and Physiology2014;41(7):509‐13. ">Rajanandh 2015</a> used tiotropium HandiHaler 18 mcg daily, but only one of these contributed data to at least one meta‐analysis. The remaining study, which was terminated (<a href="./references#CD011438-bbs2-0003" title="NCT00706446 . Genotype stratified treatment with anticholinergic vs. beta‐agonist (long acting) and exacerbations (GABLE). clinicaltrials.gov/show/NCT00706446 (accessed 18 December 2014). ">NCT00706446</a>), did not state the type and dose of tiotropium and did not contribute any data. </p> <p>The LABA used for comparison was salmeterol 50 mcg twice daily in <a href="./references#CD011438-bbs2-0001" title="BatemanED , KornmannO , SchmidtP , PivovarovaA , EngelM , FabbriLM . Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16‐Arg/Arg patients with asthma. Journal of Allergy and Clinical Immunology2011;128(2):315‐22. NCT00350207 . A 16‐week randomised, placebo‐controlled, double‐blind, double‐dummy, parallel‐group study comparing the efficacy and safety of tiotropium inhalation solution delivered by the Respimat Inhaler (2 actuations of 2.5 mcg once daily) with that of salmeterol from the hydrofluoroalkane metered dose inhaler (2 actuations of 25 mcg twice daily) in moderate persistent asthma patients with the B16‐Arg/Arg genotype. clinicaltrials.gov/show/NCT00350207 (accessed 18 December 2014). ">NCT00350207</a><a href="./references#CD011438-bbs2-0002" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). clinicaltrials.gov/show/NCT00565266 (accessed 14 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">NCT00565266</a>, <a href="./references#CD011438-bbs2-0004" title="NCT01172808 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® Inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 Weeks in moderate persistent asthma. clinicaltrials.gov/show/NCT01172808 (accessed 18 December 2014). ">NCT01172808</a> and <a href="./references#CD011438-bbs2-0005" title="CasaleT , BleeckerE , MeltzerE , PizzichiniE , SchmidtO , BatemanE , et al. Phase III trials to investigate tiotropium as add‐on therapy to inhaled corticosteroids for patients with symptomatic asthma: trial design and planned statistical analyses. Allergy2013;68:377. CasaleTB , BatemanED , DahlR , PizzichiniE , VandewalkerML , VirchowJC , et al. Tiotropium Respimat (R) add‐on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of T(H)2 inflammatory status. Journal of Allergy and Clinical Immunology2014;133(2):Ab5. NCT01172821 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® Inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 Weeks in moderate persistent asthma. clinicaltrials.gov/show/NCT01172821 (accessed 18 December 2014). ">NCT01172821</a>, the four studies comprising most of the analyses. <a href="./references#CD011438-bbs2-0003" title="NCT00706446 . Genotype stratified treatment with anticholinergic vs. beta‐agonist (long acting) and exacerbations (GABLE). clinicaltrials.gov/show/NCT00706446 (accessed 18 December 2014). ">NCT00706446</a> and <a href="./references#CD011438-bbs2-0006" title="NCT01290874 . Blacks and exacerbations on LABA vs. tiotropium (BELT). clinicaltrials.gov/show/NCT01290874 (accessed 18 December 2014). ">NCT01290874</a> allowed salmeterol 50 mcg or formoterol 12 mcg, both twice daily, but neither contributed data to the analyses. <a href="./references#CD011438-bbs2-0007" title="RajanandhMG , NageswariAD , IlangoK . Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxofylline, and tiotropium with budesonide: a randomized controlled study. Clinical Therapeutics2014;36(4):526‐33. ">Rajanandh 2014</a> and <a href="./references#CD011438-bbs2-0008" title="IlangoK . A clinical trial to study the effects of few anti asthmatic drug combinations on asthma patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2012/08/002915 (accessed 8 January 2015). RajanandhMG , NageswariAD , IlangoK . Assessment of montelukast, doxofylline, and tiotropium with budesonide for the treatment of asthma: which is the best among the second‐line treatment? A randomized trial. Clinical Therapeutics2015;37(2):41826. RajanandhMG , NageswariAD , IlangoK . Assessment of various second‐line medications in addition to inhaled corticosteroid in asthma patients: a randomized trial. Clinical and Experimental Pharmacology and Physiology2014;41(7):509‐13. ">Rajanandh 2015</a> used formoterol 12 mcg twice daily. </p> <p>The ICS used in the intervention and comparison groups varied. Some studies included the ICS as part of the randomised treatment issued by the investigators, and others stipulated a specific dose regimen as part of the inclusion criteria. <a href="./references#CD011438-bbs2-0001" title="BatemanED , KornmannO , SchmidtP , PivovarovaA , EngelM , FabbriLM . Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16‐Arg/Arg patients with asthma. Journal of Allergy and Clinical Immunology2011;128(2):315‐22. NCT00350207 . A 16‐week randomised, placebo‐controlled, double‐blind, double‐dummy, parallel‐group study comparing the efficacy and safety of tiotropium inhalation solution delivered by the Respimat Inhaler (2 actuations of 2.5 mcg once daily) with that of salmeterol from the hydrofluoroalkane metered dose inhaler (2 actuations of 25 mcg twice daily) in moderate persistent asthma patients with the B16‐Arg/Arg genotype. clinicaltrials.gov/show/NCT00350207 (accessed 18 December 2014). ">NCT00350207</a> used budesonide at 400 to 1000 mcg (low to medium dose), <a href="./references#CD011438-bbs2-0002" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). clinicaltrials.gov/show/NCT00565266 (accessed 14 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">NCT00565266</a> used beclomethasone dipropionate 80 mcg twice daily (low dose), and <a href="./references#CD011438-bbs2-0007" title="RajanandhMG , NageswariAD , IlangoK . Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxofylline, and tiotropium with budesonide: a randomized controlled study. Clinical Therapeutics2014;36(4):526‐33. ">Rajanandh 2014</a> and <a href="./references#CD011438-bbs2-0008" title="IlangoK . A clinical trial to study the effects of few anti asthmatic drug combinations on asthma patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2012/08/002915 (accessed 8 January 2015). RajanandhMG , NageswariAD , IlangoK . Assessment of montelukast, doxofylline, and tiotropium with budesonide for the treatment of asthma: which is the best among the second‐line treatment? A randomized trial. Clinical Therapeutics2015;37(2):41826. RajanandhMG , NageswariAD , IlangoK . Assessment of various second‐line medications in addition to inhaled corticosteroid in asthma patients: a randomized trial. Clinical and Experimental Pharmacology and Physiology2014;41(7):509‐13. ">Rajanandh 2015</a> used budesonide 400 mcg (low dose). The twin studies, <a href="./references#CD011438-bbs2-0004" title="NCT01172808 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® Inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 Weeks in moderate persistent asthma. clinicaltrials.gov/show/NCT01172808 (accessed 18 December 2014). ">NCT01172808</a> and <a href="./references#CD011438-bbs2-0005" title="CasaleT , BleeckerE , MeltzerE , PizzichiniE , SchmidtO , BatemanE , et al. Phase III trials to investigate tiotropium as add‐on therapy to inhaled corticosteroids for patients with symptomatic asthma: trial design and planned statistical analyses. Allergy2013;68:377. CasaleTB , BatemanED , DahlR , PizzichiniE , VandewalkerML , VirchowJC , et al. Tiotropium Respimat (R) add‐on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of T(H)2 inflammatory status. Journal of Allergy and Clinical Immunology2014;133(2):Ab5. NCT01172821 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® Inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 Weeks in moderate persistent asthma. clinicaltrials.gov/show/NCT01172821 (accessed 18 December 2014). ">NCT01172821</a>, asked participants to continue their usual ICS at a stable, medium dose. <a href="./references#CD011438-bbs2-0003" title="NCT00706446 . Genotype stratified treatment with anticholinergic vs. beta‐agonist (long acting) and exacerbations (GABLE). clinicaltrials.gov/show/NCT00706446 (accessed 18 December 2014). ">NCT00706446</a> allowed ICS at variable dosing based on the person's prior dose and the physician's judgement, and <a href="./references#CD011438-bbs2-0006" title="NCT01290874 . Blacks and exacerbations on LABA vs. tiotropium (BELT). clinicaltrials.gov/show/NCT01290874 (accessed 18 December 2014). ">NCT01290874</a> did not describe the ICS used. </p> </section> <section id="CD011438-sec-0069"> <h5 class="title">Outcomes and analysis structure</h5> <p>We have presented pooled data without subgroups for all of the pre‐specified outcomes under the Comparison 1, LAMA add‐on versus LABA add‐on. Continuous data were available as means and standard error for most of the studies, so could be entered using the Review Manager 5 calculator (<a href="./references#CD011438-bbs2-0069" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). However, the continuous data for <a href="./references#CD011438-bbs2-0002" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). clinicaltrials.gov/show/NCT00565266 (accessed 14 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">NCT00565266</a> had to be entered as adjusted between‐group differences to account for the trial's cross‐over design, so outcomes to which the study contribute data were analysed with GIV. </p> <p>In general, four studies made up the majority of the analyses: three parallel (<a href="./references#CD011438-bbs2-0001" title="BatemanED , KornmannO , SchmidtP , PivovarovaA , EngelM , FabbriLM . Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16‐Arg/Arg patients with asthma. Journal of Allergy and Clinical Immunology2011;128(2):315‐22. NCT00350207 . A 16‐week randomised, placebo‐controlled, double‐blind, double‐dummy, parallel‐group study comparing the efficacy and safety of tiotropium inhalation solution delivered by the Respimat Inhaler (2 actuations of 2.5 mcg once daily) with that of salmeterol from the hydrofluoroalkane metered dose inhaler (2 actuations of 25 mcg twice daily) in moderate persistent asthma patients with the B16‐Arg/Arg genotype. clinicaltrials.gov/show/NCT00350207 (accessed 18 December 2014). ">NCT00350207</a>; <a href="./references#CD011438-bbs2-0004" title="NCT01172808 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® Inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 Weeks in moderate persistent asthma. clinicaltrials.gov/show/NCT01172808 (accessed 18 December 2014). ">NCT01172808</a>; <a href="./references#CD011438-bbs2-0005" title="CasaleT , BleeckerE , MeltzerE , PizzichiniE , SchmidtO , BatemanE , et al. Phase III trials to investigate tiotropium as add‐on therapy to inhaled corticosteroids for patients with symptomatic asthma: trial design and planned statistical analyses. Allergy2013;68:377. CasaleTB , BatemanED , DahlR , PizzichiniE , VandewalkerML , VirchowJC , et al. Tiotropium Respimat (R) add‐on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of T(H)2 inflammatory status. Journal of Allergy and Clinical Immunology2014;133(2):Ab5. NCT01172821 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® Inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 Weeks in moderate persistent asthma. clinicaltrials.gov/show/NCT01172821 (accessed 18 December 2014). ">NCT01172821</a>) and one cross‐over (<a href="./references#CD011438-bbs2-0002" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). clinicaltrials.gov/show/NCT00565266 (accessed 14 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">NCT00565266</a>). Two of these studies included two doses of tiotropium that were merged in the main analysis and dealt with separately for the primary outcomes in subgroups in Comparison 2 (adjusting for double counting of the control group). The two dose groups from these two studies were also compared head‐to‐head for the primary outcomes in Comparison 3 (LAMA dose head‐to‐head). </p> <p>Exacerbations were generally poorly reported. Much of the data analysed for 'Exacerbations requiring hospital admission' were extracted from serious adverse events coded as 'asthma' using Medical Dictionary for Regulatory Activities (MedDRA) terminology. This was deemed appropriate since ClinicalTrials.gov defines serious adverse events as those that "result in death, require either inpatient hospitalisation or the prolongation of hospitalisation, are life‐threatening, result in a persistent or significant disability/incapacity or result in a congenital anomaly/birth defect". However, we did not include non‐serious adverse event data coded as 'asthma' in the primary outcome 'Exacerbations requiring OCS', as the definition was not sufficiently specific and may have included events that were either more or less severe. For this reason, we analysed the asthma adverse event data as a post‐hoc outcome separate from the pre‐specified 'Exacerbations requiring OCS'. </p> <p>Four studies reported asthma‐related quality of life on the AQLQ, and <a href="./references#CD011438-bbs2-0008" title="IlangoK . A clinical trial to study the effects of few anti asthmatic drug combinations on asthma patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2012/08/002915 (accessed 8 January 2015). RajanandhMG , NageswariAD , IlangoK . Assessment of montelukast, doxofylline, and tiotropium with budesonide for the treatment of asthma: which is the best among the second‐line treatment? A randomized trial. Clinical Therapeutics2015;37(2):41826. RajanandhMG , NageswariAD , IlangoK . Assessment of various second‐line medications in addition to inhaled corticosteroid in asthma patients: a randomized trial. Clinical and Experimental Pharmacology and Physiology2014;41(7):509‐13. ">Rajanandh 2015</a> used the St George's Respiratory Questionnaire (SGRQ). We reported the SGRQ data separately in the results rather than combining it using SMD with the AQLQ data so the results are easier to interpret on the relevant scales. </p> <p>The studies used several measures of lung function that could not be compiled meaningfully in a single meta‐analysis (trough peak expiratory flow (PEF), trough and peak FEV<sub>1</sub>, percentage predicted FEV<sub>1</sub>, and trough and peak forced vital capacity (FVC)). <a href="./references#CD011438-bbs2-0007" title="RajanandhMG , NageswariAD , IlangoK . Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxofylline, and tiotropium with budesonide: a randomized controlled study. Clinical Therapeutics2014;36(4):526‐33. ">Rajanandh 2014</a> and <a href="./references#CD011438-bbs2-0008" title="IlangoK . A clinical trial to study the effects of few anti asthmatic drug combinations on asthma patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2012/08/002915 (accessed 8 January 2015). RajanandhMG , NageswariAD , IlangoK . Assessment of montelukast, doxofylline, and tiotropium with budesonide for the treatment of asthma: which is the best among the second‐line treatment? A randomized trial. Clinical Therapeutics2015;37(2):41826. RajanandhMG , NageswariAD , IlangoK . Assessment of various second‐line medications in addition to inhaled corticosteroid in asthma patients: a randomized trial. Clinical and Experimental Pharmacology and Physiology2014;41(7):509‐13. ">Rajanandh 2015</a> both measured percentage predicted FEV<sub>1</sub>, although only <a href="./references#CD011438-bbs2-0007" title="RajanandhMG , NageswariAD , IlangoK . Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxofylline, and tiotropium with budesonide: a randomized controlled study. Clinical Therapeutics2014;36(4):526‐33. ">Rajanandh 2014</a> data in a format that could have been entered into a meta‐analysis, so these data have been summarised narratively. We chose to analyse different measures of lung function separately and have described the data for each in the results. Trough FEV<sub>1</sub> was pre‐specified as our preferred measure. </p> </section> </section> <section id="CD011438-sec-0070"> <h4 class="title">Excluded studies</h4> <p>We examined the full‐text reports for 19 studies, which we ultimately excluded. We excluded seven studies, with 11 associated records, because they used the wrong comparator for this review (<a href="./references#CD011438-bbs2-0014" title="CorrenJ , FrewA , EngelM , SchmidtH , Moroni‐ZentgrafP , KerstjensHAM . Tiotropium as add‐on therapy to ICS+LABA in patients with symptomatic severe asthma: spirometric assessment over 24 hours [Abstract]. American College of Chest Physicians2013;144(4):91A. KerstjensHAM , EngelM , DahlR , PaggiaroP , BeckE , VandewalkerM , et al. Tiotropium in asthma poorly controlled with standard combination therapy. New England Journal of Medicine2012;367(13):1198‐207. VandewalkerML , EngelM , SchmidtH , SieboldW , Moroni‐ZentgrafP , KerstjensH , et al. Efficacy of tiotropium in patients with asthma in relation to allergic status [Abstract]. Journal of Allergy and Clinical Immunology2013;131:AB1. ">Kerstjens 2012</a>; <a href="./references#CD011438-bbs2-0018" title="NCT00772538 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via RespimatÂ® inhaler (5 mcg/day) over 48 weeks as add‐on controller therapy on top of usual care in patients with severe persistent asthma. www.clinicaltrials.gov/ct2/show/NCT00772538 (accessed 8 January 2015). ">NCT00772538</a>; <a href="./references#CD011438-bbs2-0019" title="NCT00776984 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (5 mcg/day) over 48 weeks as add‐on controller therapy on top of usual care in patients with severe persistent asthma. www.clinicaltrials.gov/ct2/show/NCT00776984 (accessed 8 January 2015). ">NCT00776984</a>; <a href="./references#CD011438-bbs2-0020" title="NCT01316380 . A phase III, randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 ug and 5 ug once daily) compared to placebo over 12 weeks in mild persistent asthma. www.clinicaltrials.gov/show/NCT01316380 (accessed 15 January 2015). PaggiaroP , EngelM , TudoricN , ForstnerB , RadeczkyE , ZubekV , et al. Phase III trial of tiotropium as add‐on therapy to low‐dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses [Abstract]. European Respiratory Journal2013;42 (Suppl 57):877s. PaggiaroP , HalpinDMG , BuhlR , EngelM , ZubekV , BlahovaZ , et al. Tiotropium Respimat add‐on to inhaled corticosteroids improves lung function in patients with symptomatic mild asthma: results from a phase III trial. Journal of Allergy and Clinical Immunology2014;133(2):AB4. ">NCT01316380</a>; <a href="./references#CD011438-bbs2-0021" title="NCT01340209 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate safety and efficacy of tiotropium inhalation solution delivered via Respimat inhaler (2.5 and 5 µg once daily) compared with placebo over 52 weeks in patients with moderate to severe persistent asthma. www.clinicaltrials.gov/show/NCT01340209 (accessed 15 January 2015). ">NCT01340209</a>; <a href="./references#CD011438-bbs2-0025" title="NCT02066298 . Steroids in eosinophil negative asthma. www.clinicaltrials.gov/ct2/show/NCT02066298 (accessed 8 January 2015). ">NCT02066298</a>; <a href="./references#CD011438-bbs2-0026" title="NCT02127697 . A randomized, double‐blind, parallel group, 52‐week study evaluating the efficacy, safety and tolerability of NVA237 in patients with poorly controlled asthma. www.clinicaltrials.gov/ct2/show/NCT02127697 (accessed 8 January 2015). ">NCT02127697</a>). All of these compared a LAMA with placebo, either alone or on top of other treatments such as ICS or LABA plus ICS. One study considered the effects of a smoking cessation programme among people with asthma, and was not relevant to the research question (<a href="./references#CD011438-bbs2-0024" title="NCT01696214 . SAPS: Smoking Asthmatics Pilot Study. clinicaltrials.gov/show/NCT01696214 (accessed 18 December 2014). ">NCT01696214</a>). We excluded six studies because they were shorter than the pre‐specified 12 weeks. Two were single‐dose studies (<a href="./references#CD011438-bbs2-0009" title="Chest Research Foundation. A clinical trial comparing bronchodilator effects of two drugs, tiotropium bromide and formoterol fumarate each over 24 hours in subjects with asthma. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2008/091/000306 (accessed 8 January 2015). ">CTRI/2008/091/000306</a>; <a href="./references#CD011438-bbs2-0013" title="Fukuoka National Hospital. Study for effects of tiotropium on smokers and non‐smokers with bronchial asthma. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000010352 (accessed 8 January 2015). ">JPRN‐UMIN000010352</a>), and four administered treatments for two to three weeks (<a href="./references#CD011438-bbs2-0010" title="Boehringer Ingelheim PharmaGmbH , Co.KG . The effect of tiotropium‐bromide on deep inspiration‐induced bronchodilation and airway responsiveness in asthma ‐ tiotropium‐bromide and lung mechanics. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006‐003385‐34‐NL (accessed 8 January 2015). ">EUCTR2006‐003385‐34‐NL</a>; <a href="./references#CD011438-bbs2-0017" title="NCT00557700 . Study to investigate the effect of inhaled tiotropium bromide on neurokinin‐A induced bronchoconstriction in patients with mild‐to‐moderate asthma. www.clinicaltrials.gov/ct2/show/NCT00557700 (accessed 8 January 2015). ">NCT00557700</a>; <a href="./references#CD011438-bbs2-0022" title="NCT01573624 . Evaluate the safety, efficacy and dose response of GSK573719 in combination with fluticasone furoate in subjects with asthma (ILA115938). clinicaltrials.gov/show/NCT01573624 (accessed 18 December 2014). ">NCT01573624</a>; <a href="./references#CD011438-bbs2-0023" title="NCT01641692 . A multi‐national, randomized, double‐blind, placebo‐controlled, 3‐period crossover study with GSK 573719 as monotherapy in adult subjects with asthma. www.clinicaltrials.gov/ct2/show/NCT01641692 (accessed 8 January 2015). ">NCT01641692</a>). Some of these studies also used the wrong comparator for this review. Three studies recruited the wrong population for this review: two studied people with COPD (<a href="./references#CD011438-bbs2-0011" title="Saitama Medical University. Randomized clinical study with tiotropium and formoterol/budesonide in COPD with asthma. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000003618 (accessed 8 January 2015). ">JPRN‐UMIN000003618</a>; <a href="./references#CD011438-bbs2-0012" title="EACC (Ehime Asthma COPDConference) . Add‐on therapy for COPD receiving inhaled bronchodilators. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000005459 (accessed 8 January 2015). ">JPRN‐UMIN000005459</a>), and one recruited adolescents rather than adults with asthma (<a href="./references#CD011438-bbs2-0027" title="VogelbergC , EngelM , Moroni‐ZentgrafP , Leonaviciute‐KlimantavicieneM , SigmundR , DownieJ , et al. Once‐daily tiotropium in adolescents with symptomatic asthma despite inhaled corticosteroid treatment: a dose‐ranging study [Abstract]. Clinical and Translational Allergy2014;4((Suppl 1)):2. ">Vogelberg 2014</a>). We excluded one study because it used an observational rather than randomised controlled design (<a href="./references#CD011438-bbs2-0016" title="National Jewish Health. Examining the link between obesity, inflammation, and response to asthma medications. clinicaltrials.gov/show/NCT00557180 (accessed 8 January 2015). ">NCT00557180</a>), and one because the protocol was withdrawn before any participants were enrolled (<a href="./references#CD011438-bbs2-0015" title="NCT00546234 . Assessing treatment options for smokers with asthma. www.clinicaltrials.gov/ct2/show/NCT00546234 (accessed 8 January 2015). ">NCT00546234</a>). </p> </section> </section> <section id="CD011438-sec-0071"> <h3 class="title">Risk of bias in included studies</h3> <p>Overall, several studies were given high risk of bias ratings, particularly in the blinding domains and selective reporting, and there was some uncertainty in others, mostly due to insufficient reporting. However, most of the high risk of bias judgements were associated with studies that did not contribute data to the meta‐analyses. Risk of bias judgements are explained for each study in the <a href="./references#CD011438-sec-0127" title="">Characteristics of included studies</a> table, and <a href="#CD011438-fig-0002">Figure 2</a> shows an overview. </p> <div class="figure" id="CD011438-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011438-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011438-sec-0072"> <h4 class="title">Allocation</h4> <p>Reporting within the clinicaltrials.gov records was not detailed enough in most cases to assess this domain fully, but prior contact with the study sponsors and additional contact for this review confirmed standard practices of the industry‐funded trials warranting low risk of bias judgements (using computerised codes and automated allocation systems). We were unsure of the allocation procedures in the two trials contributing no data to the analyses. <a href="./references#CD011438-bbs2-0007" title="RajanandhMG , NageswariAD , IlangoK . Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxofylline, and tiotropium with budesonide: a randomized controlled study. Clinical Therapeutics2014;36(4):526‐33. ">Rajanandh 2014</a> and <a href="./references#CD011438-bbs2-0008" title="IlangoK . A clinical trial to study the effects of few anti asthmatic drug combinations on asthma patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2012/08/002915 (accessed 8 January 2015). RajanandhMG , NageswariAD , IlangoK . Assessment of montelukast, doxofylline, and tiotropium with budesonide for the treatment of asthma: which is the best among the second‐line treatment? A randomized trial. Clinical Therapeutics2015;37(2):41826. RajanandhMG , NageswariAD , IlangoK . Assessment of various second‐line medications in addition to inhaled corticosteroid in asthma patients: a randomized trial. Clinical and Experimental Pharmacology and Physiology2014;41(7):509‐13. ">Rajanandh 2015</a> described allocation concealment with opaque envelopes. </p> </section> <section id="CD011438-sec-0073"> <h4 class="title">Blinding</h4> <p>Three studies were open label and were rated high risk of bias for both performance and detection bias; placebos were not used to blind the participants and personnel from group allocation and there was no information in any of the reports to suggest that outcome assessment was blinded to control for detection bias. However, two of the open‐label studies did not feature in any of the meta‐analyses, and the other only contributed data to two secondary outcomes. As such, it is unlikely that the majority of results were affected by bias related to lack of blinding. </p> </section> <section id="CD011438-sec-0074"> <h4 class="title">Incomplete outcome data</h4> <p>Two studies were considered high risk of bias for attrition bias. Three studies analysed participants who completed the trial, and did not attempt to impute values for participants who dropped out, which was over 25% of the population in <a href="./references#CD011438-bbs2-0007" title="RajanandhMG , NageswariAD , IlangoK . Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxofylline, and tiotropium with budesonide: a randomized controlled study. Clinical Therapeutics2014;36(4):526‐33. ">Rajanandh 2014</a> and just under 20% in each of the relevant groups in <a href="./references#CD011438-bbs2-0008" title="IlangoK . A clinical trial to study the effects of few anti asthmatic drug combinations on asthma patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2012/08/002915 (accessed 8 January 2015). RajanandhMG , NageswariAD , IlangoK . Assessment of montelukast, doxofylline, and tiotropium with budesonide for the treatment of asthma: which is the best among the second‐line treatment? A randomized trial. Clinical Therapeutics2015;37(2):41826. RajanandhMG , NageswariAD , IlangoK . Assessment of various second‐line medications in addition to inhaled corticosteroid in asthma patients: a randomized trial. Clinical and Experimental Pharmacology and Physiology2014;41(7):509‐13. ">Rajanandh 2015</a>; one other stated that an intention‐to‐treat analysis was undertaken, but the numbers stated for each outcome suggested 20% to 21% were not accounted for. Two included studies did not report attrition (<a href="./references#CD011438-bbs2-0003" title="NCT00706446 . Genotype stratified treatment with anticholinergic vs. beta‐agonist (long acting) and exacerbations (GABLE). clinicaltrials.gov/show/NCT00706446 (accessed 18 December 2014). ">NCT00706446</a>; <a href="./references#CD011438-bbs2-0006" title="NCT01290874 . Blacks and exacerbations on LABA vs. tiotropium (BELT). clinicaltrials.gov/show/NCT01290874 (accessed 18 December 2014). ">NCT01290874</a>). The three remaining studies, which dominated the analyses, had low and even rates of attrition and were rated low risk of bias. </p> </section> <section id="CD011438-sec-0075"> <h4 class="title">Selective reporting</h4> <p>Two of the included studies were rated high risk of bias due to missing outcomes or insufficient reporting of data to allow meta‐analysis. In two others, it was unclear whether all outcomes had been reported due to lack of clarity in the listing of outcomes. One study reported data as stated in the protocol and were rated low risk of bias (<a href="./references#CD011438-bbs2-0001" title="BatemanED , KornmannO , SchmidtP , PivovarovaA , EngelM , FabbriLM . Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16‐Arg/Arg patients with asthma. Journal of Allergy and Clinical Immunology2011;128(2):315‐22. NCT00350207 . A 16‐week randomised, placebo‐controlled, double‐blind, double‐dummy, parallel‐group study comparing the efficacy and safety of tiotropium inhalation solution delivered by the Respimat Inhaler (2 actuations of 2.5 mcg once daily) with that of salmeterol from the hydrofluoroalkane metered dose inhaler (2 actuations of 25 mcg twice daily) in moderate persistent asthma patients with the B16‐Arg/Arg genotype. clinicaltrials.gov/show/NCT00350207 (accessed 18 December 2014). ">NCT00350207</a>), authors of another study provided additional data that changed our rating from unclear to low (<a href="./references#CD011438-bbs2-0002" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). clinicaltrials.gov/show/NCT00565266 (accessed 14 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">NCT00565266</a>), and missing data for two other studies were subsequently published in a pooled report, which changed the ratings from high to low (<a href="./references#CD011438-bbs2-0004" title="NCT01172808 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® Inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 Weeks in moderate persistent asthma. clinicaltrials.gov/show/NCT01172808 (accessed 18 December 2014). ">NCT01172808</a>; <a href="./references#CD011438-bbs2-0005" title="CasaleT , BleeckerE , MeltzerE , PizzichiniE , SchmidtO , BatemanE , et al. Phase III trials to investigate tiotropium as add‐on therapy to inhaled corticosteroids for patients with symptomatic asthma: trial design and planned statistical analyses. Allergy2013;68:377. CasaleTB , BatemanED , DahlR , PizzichiniE , VandewalkerML , VirchowJC , et al. Tiotropium Respimat (R) add‐on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of T(H)2 inflammatory status. Journal of Allergy and Clinical Immunology2014;133(2):Ab5. NCT01172821 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® Inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 Weeks in moderate persistent asthma. clinicaltrials.gov/show/NCT01172821 (accessed 18 December 2014). ">NCT01172821</a>). </p> </section> <section id="CD011438-sec-0076"> <h4 class="title">Other potential sources of bias</h4> <p>No additional sources of bias were identified in four studies, which were all rated low risk of bias. The three studies contributing the majority of data to the analyses were given unclear ratings, mainly because they were all funded by Boehringer Ingelheim and because there was minimal baseline information about the participants to judge whether the groups were well balanced. The remaining study was rated high risk of bias because it was terminated without a description why, and without any interim results. </p> </section> </section> <section id="CD011438-sec-0077"> <h3 class="title" id="CD011438-sec-0077">Effects of interventions</h3> <p>See: <a href="./full#CD011438-tbl-0001"><b>Summary of findings for the main comparison</b> Long‐acting muscarinic antagonists (LAMA) add‐on compared with long‐acting beta<sub>2</sub>‐agonists (LABA) add‐on for adults with asthma</a> </p> <section id="CD011438-sec-0078"> <h4 class="title">Primary outcomes</h4> <section id="CD011438-sec-0079"> <h5 class="title">Exacerbations requiring oral corticosteroids</h5> <p>Three studies reported exacerbations requiring OCS, two of which were twin trials reported as a pooled result (<a href="./references#CD011438-bbs2-0004" title="NCT01172808 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® Inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 Weeks in moderate persistent asthma. clinicaltrials.gov/show/NCT01172808 (accessed 18 December 2014). ">NCT01172808</a>; <a href="./references#CD011438-bbs2-0005" title="CasaleT , BleeckerE , MeltzerE , PizzichiniE , SchmidtO , BatemanE , et al. Phase III trials to investigate tiotropium as add‐on therapy to inhaled corticosteroids for patients with symptomatic asthma: trial design and planned statistical analyses. Allergy2013;68:377. CasaleTB , BatemanED , DahlR , PizzichiniE , VandewalkerML , VirchowJC , et al. Tiotropium Respimat (R) add‐on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of T(H)2 inflammatory status. Journal of Allergy and Clinical Immunology2014;133(2):Ab5. NCT01172821 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® Inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 Weeks in moderate persistent asthma. clinicaltrials.gov/show/NCT01172821 (accessed 18 December 2014). ">NCT01172821</a>). Three more people per 1000 would have an exacerbation on LAMA compared with LABA, but the CIs ranged from 29 fewer to 61 more. The effect was too imprecise to determine whether one treatment reduced these exacerbations more than the other (OR 1.05, 95% CI 0.50 to 2.18; 1753 participants; 3 studies; low quality; <a href="./references#CD011438-fig-0003" title="">Analysis 1.1</a>). The evidence was downgraded due to this uncertainty, and for inconsistency because the two results (pooled twin trials and the cross‐over study) gave different directions of effect. </p> <p>We also analysed data extracted from the non‐serious adverse event tables that were recorded as 'asthma'. It is unclear what sort of event qualified under this outcome, but three studies reported data in this way. The pooled effect was more precise and did not show that LAMA or LABA reduced these events more than the other (OR 0.95, 95% CI 0.74 to 1.22; 1839 participants; 3 studies; I<sup>2</sup> = 0%; moderate quality; <a href="./references#CD011438-fig-0015" title="">Analysis 1.13</a>). Evidence for this additional post‐hoc analysis was rated moderate quality after being downgraded once for indirectness, as it was a proxy outcome with uncertainties about the definitions used. </p> </section> <section id="CD011438-sec-0080"> <h5 class="title">Quality of life</h5> <p>People treated with LAMA add‐on scored slightly worse than LABA add‐on for quality of life measured on the AQLQ (MD ‐0.12, 95% CI ‐0.18 to ‐0.05; 1745 participants; 4 studies; I<sup>2</sup> = 0%; <a href="./references#CD011438-fig-0004" title="">Analysis 1.2</a>). The difference was statistically significant but both CIs fell well below the established minimal clinically important difference (MCID) of 0.5 on the AQLQ, so it is unlikely to be a clinically meaningful difference. The evidence was rated high quality, as the effect was relatively precise and consistent, and the studies were of good methodological quality. </p> <p><a href="./references#CD011438-bbs2-0008" title="IlangoK . A clinical trial to study the effects of few anti asthmatic drug combinations on asthma patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2012/08/002915 (accessed 8 January 2015). RajanandhMG , NageswariAD , IlangoK . Assessment of montelukast, doxofylline, and tiotropium with budesonide for the treatment of asthma: which is the best among the second‐line treatment? A randomized trial. Clinical Therapeutics2015;37(2):41826. RajanandhMG , NageswariAD , IlangoK . Assessment of various second‐line medications in addition to inhaled corticosteroid in asthma patients: a randomized trial. Clinical and Experimental Pharmacology and Physiology2014;41(7):509‐13. ">Rajanandh 2015</a> measured quality of life using the SGRQ but only presented data graphically. Total scores in both groups were significantly improved after six months, but the mean score in the LAMA group was worse than the LABA group. There was no information about variance and whether the difference was statistically significant. </p> </section> <section id="CD011438-sec-0081"> <h5 class="title">Any serious adverse event</h5> <p>The CIs were too wide to determine whether serious adverse events were more likely with LAMA or LABA because so few events occurred in the studies (OR 0.84, 95% CI 0.41 to 1.73; 2012 participants; 4 studies; I<sup>2</sup> = 23%; low quality; <a href="./references#CD011438-fig-0005" title="">Analysis 1.3</a>). The estimate suggested 4 fewer people per 1000 would have serious adverse events on LAMA, but the CIs ranged from 17 fewer to 15 more, and the evidence was downgraded twice for this reason. </p> </section> </section> <section id="CD011438-sec-0082"> <h4 class="title">Secondary outcomes</h4> <section id="CD011438-sec-0083"> <h5 class="title">Exacerbations requiring hospitalisation</h5> <p>The evidence for this more serious form of exacerbation was very low quality, mostly because events were rare in the studies. There were slightly fewer exacerbations in the LAMA add‐on groups, but the CIs were too wide to judge whether LAMA or LABA were more effective, and visually there was inconsistency between study results (OR 0.72, 95% CI 0.18 to 2.92; 2022 participants; 4 studies; I<sup>2</sup> = 20%; very low quality; <a href="./references#CD011438-fig-0006" title="">Analysis 1.4</a>). </p> </section> <section id="CD011438-sec-0084"> <h5 class="title">Lung function</h5> <p>We downgraded all of the lung function outcomes, with the exception of trough FEV<sub>1</sub>, which was our preferred measure, because they were reported by the same few studies and we were unsure of their relevance to the question on top of our preferred measure (i.e. indirectness). </p> <section id="CD011438-sec-0085"> <h6 class="title">Forced expiratory volume in one second</h6> <p>Trough FEV<sub>1</sub> was higher in people given LAMA add‐on compared with people given LABA add‐on, but again this effect was relatively small and there was heterogeneity between study results (downgraded once) (MD 0.05 L, 95% CI 0.01 to 0.09; 1745 participants; 4 studies; I<sup>2</sup> = 46%; moderate quality; <a href="./references#CD011438-fig-0007" title="">Analysis 1.5</a>). Three studies reported peak FEV<sub>1</sub> but two were within three hours of bronchodilation and one immediately after four puffs of albuterol, so we did not pool the data. <a href="./references#CD011438-bbs2-0007" title="RajanandhMG , NageswariAD , IlangoK . Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxofylline, and tiotropium with budesonide: a randomized controlled study. Clinical Therapeutics2014;36(4):526‐33. ">Rajanandh 2014</a> reported percentage predicted FEV<sub>1</sub> and showed that LAMA add‐on was less effective than LABA add‐on, but they did not report when the measurement was taken (i.e. pre‐ or post‐bronchodilator), so it may not have been a fair comparison given the faster onset of formoterol. <a href="./references#CD011438-bbs2-0008" title="IlangoK . A clinical trial to study the effects of few anti asthmatic drug combinations on asthma patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2012/08/002915 (accessed 8 January 2015). RajanandhMG , NageswariAD , IlangoK . Assessment of montelukast, doxofylline, and tiotropium with budesonide for the treatment of asthma: which is the best among the second‐line treatment? A randomized trial. Clinical Therapeutics2015;37(2):41826. RajanandhMG , NageswariAD , IlangoK . Assessment of various second‐line medications in addition to inhaled corticosteroid in asthma patients: a randomized trial. Clinical and Experimental Pharmacology and Physiology2014;41(7):509‐13. ">Rajanandh 2015</a> also measured percentage predicted FEV<sub>1</sub> and suggested that tiotropium was less effective than formoterol, but did not report data sufficiently to combine it with <a href="./references#CD011438-bbs2-0007" title="RajanandhMG , NageswariAD , IlangoK . Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxofylline, and tiotropium with budesonide: a randomized controlled study. Clinical Therapeutics2014;36(4):526‐33. ">Rajanandh 2014</a> in a meta‐analysis. </p> </section> <section id="CD011438-sec-0086"> <h6 class="title">Peak expiratory flow</h6> <p>People treated with LAMA add‐on had slightly better trough PEF than those given LABA add‐on, but the difference was small (MD 5.78 L/minute, 95% CI 0.86 to 10.71; 1745 participants; 4 studies; I<sup>2</sup> = 0%; moderate quality; <a href="./references#CD011438-fig-0009" title="">Analysis 1.7</a>). </p> </section> <section id="CD011438-sec-0087"> <h6 class="title">Forced vital capacity</h6> <p>Trough FVC was slightly higher in people taking LAMA add‐on compared with people taking LABA add‐on, but the CIs included the possibility that LABA were better (MD 0.03 L, 95% CI ‐0.02 to 0.07; 1745 participants; 3 studies; I<sup>2</sup> = 0%; <a href="./references#CD011438-fig-0010" title="">Analysis 1.8</a>). The two studies reporting peak FVC did not detect a difference between the two add‐on therapies, with the CIs including benefit on either treatment (MD ‐0.00 L, 95% CI ‐0.04 to 0.03; 1483 participants; 2 studies; I<sup>2</sup> = 4%; <a href="./references#CD011438-fig-0011" title="">Analysis 1.9</a>). The evidence for both FVC outcomes was only downgraded for indirectness (see above), and rated moderate quality. </p> </section> </section> <section id="CD011438-sec-0088"> <h5 class="title">Asthma control</h5> <p>Three studies reporting the ACQ showed that the asthma of people taking LAMA add‐on were slightly less controlled than people taking LABA add‐on (MD 0.06, 95% CI 0.00 to 0.13; 1483 participants; 3 studies; I<sup>2</sup> = 0%; <a href="./references#CD011438-fig-0012" title="">Analysis 1.10</a>). As with the AQLQ, the evidence was rated high quality but the effect and its CIs were not in the range of the MCID (also 0.5), and touched the line of no effect, so the difference between the treatments was unlikely to be of clinical significance. </p> <p>The two twin studies reported the number of people meeting criteria for 'response' on the ACQ, defined as people whose score improved by at least the MCID. The studies detected no difference between the groups, and the CIs were too wide to infer equivalence of the two treatments (OR 0.91, 95% CI 0.73 to 1.13; 1563 participants; 2 studies; I<sup>2</sup> = 0%; <a href="./references#CD011438-fig-0013" title="">Analysis 1.11</a>). </p> </section> <section id="CD011438-sec-0089"> <h5 class="title">Any adverse events</h5> <p>More people taking LAMA had an adverse event than people taking LABA, but the difference was not statistically significant (OR 1.11, 95% CI 0.92 to 1.35; 1839 participants; 3 studies; I<sup>2</sup> = 0%; <a href="./references#CD011438-fig-0014" title="">Analysis 1.12</a>). The CIs were relatively tight but not so much that equivalence of the two treatments could be concluded. </p> </section> </section> <section id="CD011438-sec-0090"> <h4 class="title">Subgroup analyses</h4> <section id="CD011438-sec-0091"> <h5 class="title">Duration of therapy</h5> <p>The four studies reporting data for the primary outcomes were all less than six months' duration, so we could not perform a subgroup analysis as planned. </p> </section> <section id="CD011438-sec-0092"> <h5 class="title">Corticosteroid dose</h5> <p>We did not conduct a subgroup analysis on the basis of corticosteroid dose because there was not a clear comparison to be made between the four studies contributing data to the primary outcomes. <a href="./references#CD011438-bbs2-0004" title="NCT01172808 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® Inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 Weeks in moderate persistent asthma. clinicaltrials.gov/show/NCT01172808 (accessed 18 December 2014). ">NCT01172808</a> and <a href="./references#CD011438-bbs2-0005" title="CasaleT , BleeckerE , MeltzerE , PizzichiniE , SchmidtO , BatemanE , et al. Phase III trials to investigate tiotropium as add‐on therapy to inhaled corticosteroids for patients with symptomatic asthma: trial design and planned statistical analyses. Allergy2013;68:377. CasaleTB , BatemanED , DahlR , PizzichiniE , VandewalkerML , VirchowJC , et al. Tiotropium Respimat (R) add‐on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of T(H)2 inflammatory status. Journal of Allergy and Clinical Immunology2014;133(2):Ab5. NCT01172821 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® Inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 Weeks in moderate persistent asthma. clinicaltrials.gov/show/NCT01172821 (accessed 18 December 2014). ">NCT01172821</a> allowed any stable medium dose of corticosteroid, <a href="./references#CD011438-bbs2-0002" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). clinicaltrials.gov/show/NCT00565266 (accessed 14 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">NCT00565266</a> allowed low‐dose beclomethasone, and <a href="./references#CD011438-bbs2-0001" title="BatemanED , KornmannO , SchmidtP , PivovarovaA , EngelM , FabbriLM . Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16‐Arg/Arg patients with asthma. Journal of Allergy and Clinical Immunology2011;128(2):315‐22. NCT00350207 . A 16‐week randomised, placebo‐controlled, double‐blind, double‐dummy, parallel‐group study comparing the efficacy and safety of tiotropium inhalation solution delivered by the Respimat Inhaler (2 actuations of 2.5 mcg once daily) with that of salmeterol from the hydrofluoroalkane metered dose inhaler (2 actuations of 25 mcg twice daily) in moderate persistent asthma patients with the B16‐Arg/Arg genotype. clinicaltrials.gov/show/NCT00350207 (accessed 18 December 2014). ">NCT00350207</a> allowed any dose between 400 and 1000 mcg budesonide but did not report the mean dose taken during the study. </p> </section> <section id="CD011438-sec-0093"> <h5 class="title">Dose and type of long‐acting beta<sub>2</sub>‐agonists </h5> <p>All four studies reporting data for the primary outcomes used salmeterol 50 mcg twice daily in the comparison group, so there was no subgroup comparison to be made. </p> </section> <section id="CD011438-sec-0094"> <h5 class="title">Dose and type of long‐acting muscarinic antagonists</h5> <p>A subgroup analysis of the exacerbations (OCS) data comparing dose and type of LAMA showed some differences in effect that were not statistically different from each other (test for subgroup differences: I<sup>2</sup> = 25%, P value = 0.26; <a href="./references#CD011438-fig-0016" title="">Analysis 2.1</a>). Since so few studies reported the outcome, it was difficult to judge whether there was a true difference between the two Respimat doses and HandiHaler 18 mcg. </p> <p>The same four studies appeared in analyses for the AQLQ and serious adverse events outcomes. There was no evidence of significant subgroup differences between Respimat 2.5 mcg, Respimat 5 mcg, and HandiHaler 18 mcg in either analysis (<a href="./references#CD011438-fig-0017" title="">Analysis 2.2</a> and <a href="./references#CD011438-fig-0018" title="">Analysis 2.3</a>; test for subgroup differences I<sup>2</sup> = 0% in both cases). </p> <p>For all three primary outcomes, we also conducted a head‐to‐head comparison of Respimat 2.5 mcg versus Respimat 5 mcg using the two trials including both doses (<a href="./references#CD011438-bbs2-0004" title="NCT01172808 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® Inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 Weeks in moderate persistent asthma. clinicaltrials.gov/show/NCT01172808 (accessed 18 December 2014). ">NCT01172808</a>; <a href="./references#CD011438-bbs2-0005" title="CasaleT , BleeckerE , MeltzerE , PizzichiniE , SchmidtO , BatemanE , et al. Phase III trials to investigate tiotropium as add‐on therapy to inhaled corticosteroids for patients with symptomatic asthma: trial design and planned statistical analyses. Allergy2013;68:377. CasaleTB , BatemanED , DahlR , PizzichiniE , VandewalkerML , VirchowJC , et al. Tiotropium Respimat (R) add‐on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of T(H)2 inflammatory status. Journal of Allergy and Clinical Immunology2014;133(2):Ab5. NCT01172821 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® Inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 Weeks in moderate persistent asthma. clinicaltrials.gov/show/NCT01172821 (accessed 18 December 2014). ">NCT01172821</a>). The head‐to‐head comparisons showed no statistically significant difference with regards to exacerbations requiring OCS, although fewer occurred in the lower‐dose group OR 0.69, 95% CI 0.40 to 1.22; 1036 participants; 1 study; <a href="./references#CD011438-fig-0019" title="">Analysis 3.1</a>). The doses were similar with respect to AQLQ score (MD 0.01, 95% CI ‐0.09 to 0.10; 973 participants; 2 studies; I<sup>2</sup> = 0%; <a href="./references#CD011438-fig-0020" title="">Analysis 3.2</a>) and rates of serious adverse events (OR 1.09, 95% CI 0.47 to 2.49; 1036 participants; 2 studies; I<sup>2</sup> = 0%; <a href="./references#CD011438-fig-0021" title="">Analysis 3.3</a>). </p> </section> </section> <section id="CD011438-sec-0095"> <h4 class="title">Sensitivity analyses</h4> <section id="CD011438-sec-0096"> <h5 class="title">Studies at high risk of bias for blinding of participants and personnel</h5> <p>We rated the four open‐label studies included in the review at high risk of bias for blinding but they did not contribute data to the primary outcomes, so could not be excluded in a sensitivity analysis. </p> </section> <section id="CD011438-sec-0097"> <h5 class="title">Unpublished data</h5> <p>We included no conference abstracts. With the exception of additional data provided by the authors of <a href="./references#CD011438-bbs2-0002" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). clinicaltrials.gov/show/NCT00565266 (accessed 14 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">NCT00565266</a>, which was removed in the cross‐over sensitivity analysis (below), all of the data included in the primary outcomes were available in peer‐reviewed reports or publicly available websites. </p> </section> <section id="CD011438-sec-0098"> <h5 class="title">Cross‐over trials</h5> <p>We removed the cross‐over study, <a href="./references#CD011438-bbs2-0002" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). clinicaltrials.gov/show/NCT00565266 (accessed 14 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">NCT00565266</a>, from the three primary outcomes in a sensitivity analysis based on study design. </p> <p>Removing <a href="./references#CD011438-bbs2-0002" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). clinicaltrials.gov/show/NCT00565266 (accessed 14 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">NCT00565266</a> from the 'Exacerbations requiring OCS' analysis left only the pooled twin trials, which showed a more favourable effect for LAMA than the pooled result (<a href="./references#CD011438-fig-0022" title="">Analysis 4.1</a>), but the conclusions remained the same. It was not possible to determine whether one treatment was more effective than the other. The AQLQ result was very similar with the cross‐over trial removed (<a href="./references#CD011438-fig-0023" title="">Analysis 4.2</a>), and the serious adverse event effect was slightly larger in magnitude but even more imprecise without the cross‐over data (<a href="./references#CD011438-fig-0024" title="">Analysis 4.3</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011438-sec-0099" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011438-sec-0099"></div> <section id="CD011438-sec-0100"> <h3 class="title" id="CD011438-sec-0100">Summary of main results</h3> <p>We included eight studies meeting the inclusion criteria, but four double‐blind, double‐dummy studies dominated the analyses, looking primarily at tiotropium (Respimat) versus salmeterol. Trials ranged between 12 and 52 weeks, but the main four trials were all under six months' duration and contributed data from about 2000 people to most of the analyses. </p> <p>There was low quality evidence with regards to exacerbations requiring treatment with OCS with the direction of effect slightly in favour of LABA over LAMA but with very wide CIs. In absolute terms, 3 more people per 1000 had an exacerbation on LAMA compared with LABA, but the CIs ranged from 29 fewer to 61 more. Imprecision was also an issue for serious adverse events (rated low quality) and exacerbations requiring hospital admission (rated very low quality), because there were too few events in the analyses to determine whether one treatment was better than the other. </p> <p>People treated with LAMA scored slightly worse on two scales measuring quality of life (AQLQ) and asthma control (ACQ); the evidence was rated high quality but the differences were below the MCID on both scales. </p> <p>There was some evidence to support small benefits of LAMA on lung function, including on our pre‐specified preferred measure trough FEV<sub>1</sub>. However, this was not the case for all the measures that we considered; the effects were not always statistically significant or in favour of LAMA, and it was not clear whether the magnitude of the differences were clinically significant. </p> <p>More people had adverse events with LAMA but the difference with LABA was not statistically significant. </p> </section> <section id="CD011438-sec-0101"> <h3 class="title" id="CD011438-sec-0101">Overall completeness and applicability of evidence</h3> <p>The current evidence base to address this question was incomplete in several respects. We were unable to assess the robustness of the data with most of the planned sensitivity and subgroup analyses because too few studies reported the primary outcomes. All of the studies used the LAMA, tiotropium, mostly delivered via the Respimat rather than HandiHaler, so we do not know whether our findings will apply to other LAMA drugs such as glycopyrronium and aclidinium (neither of which are licensed for use in asthma at present). Similarly, since all the studies in the analyses used salmeterol as the LABA comparator, there is a possibility that formoterol or one of the once‐daily preparations (e.g. indacaterol or vilanterol) would give different results. Furthermore, there is currently no comparison of LAMA add‐on with combination formoterol plus budesonide in the 'SMART' approach as maintenance and reliever therapy, for which there is evidence of added efficacy compared with current best practice or higher doses of corticosteroid in combination therapy (<a href="./references#CD011438-bbs2-0040" title="CatesCJ , KarnerC . Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD007313.pub3] ">Cates 2013</a>; <a href="./references#CD011438-bbs2-0056" title="KewKM , KarnerC , MindusSM , FerraraG . Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD009019.pub2] ">Kew 2013</a>). The SMART approach is unique to formoterol plus budesonide due to the fast‐onset properties of formoterol, which may represent a benefit over LAMA add‐on, and this is an area for potential comparison. Overall, the use of LAMA is relatively new for asthma, with only one license extension for Spiriva Respimat used in combination with LABA plus ICS currently granted in the UK. As such, the research base is likely to grow in coming years and future versions of this review may be more able to form meaningful conclusions that account for the possible effect moderators we outlined in our planned subgroup analyses. </p> <p>As it stands, the evidence base directly comparing LAMA plus ICS with LABA plus ICS is small, and so clinicians considering the use of LAMA as an alternative to LABA will likely turn to the larger evidence bases for each drug against ICS alone. This evidence base is particularly strong for LABA, with the most recent review including 77 studies of over 20,000 people compared with four studies of about 2000 people for LAMA. This evidence bias towards the older and more commonly used LABA class of drugs has highlighted the reliable evidence for LABA add‐on both in terms of its efficacy (<a href="./references#CD011438-bbs2-0045" title="DucharmeFM , Ni ChroininM , GreenstoneI , LassersonTJ . Addition of long‐acting beta2‐agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2008, Issue 5. [DOI: 10.1002/14651858.CD005535.pub2] ">Ducharme 2008</a>), and safety concerns (<a href="./references#CD011438-bbs2-0041" title="CatesCJ , WielandLS , OleszczukM , KewKM . Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD010314.pub2] ">Cates 2014</a>), but comparing LAMA and LABA add‐on in this indirect way is not as reliable as using randomised trials comparing them directly. </p> <p>In terms of the conduct of the included studies in this review, the three open‐label studies reported very few data between them, which meant the four multi‐site double‐blind, double‐dummy studies dominated the findings. While this means the meta‐analyses are less prone to biases from within the studies, it may represent a reporting bias towards industry‐funded multicentre studies (three of the four were international trials funded by Boehringer‐Ingelheim). These studies are likely to be highly controlled and conducted to standards that may not be representative of normal medical care with respect to service provision and inhaler adherence. Another downside of these studies is their fairly strict inclusion and exclusion criteria, which may leave an uncertainty of the risk and benefits of LAMA and LABA used in certain patient subgroups not represented in the trials. For example, the cardiac adverse effects of tiotropium that have been documented in COPD trials may be dangerous for people with asthma with cardiac or renal co‐morbidity (<a href="./references#CD011438-bbs2-0061" title="Medicines and Healthcare Products Regulatory Agency (MHRA). Drug safety update: tiotropium. www.gov.uk/drug‐safety‐update/tiotropium (accessed 21 April 2015). ">MHRA 2010</a>), particularly older people with significant smoking histories. </p> <p>We chose to look specifically at adults in this review and the studies recruited similar populations with respect to demographics, where this information was available. The inclusion criteria and baseline characteristics of the included populations would suggest the results are most applicable to non‐smoking adults with moderate asthma (percentage predicted FEV<sub>1</sub> around 70%), who are experiencing symptoms on their ICS controller inhaler. Studies consistently excluded participants with histories of life‐threatening asthma and other medical illnesses, so it is unclear how this evidence may apply to these more complex populations. </p> </section> <section id="CD011438-sec-0102"> <h3 class="title" id="CD011438-sec-0102">Quality of the evidence</h3> <p>Of all the outcomes that we analysed, we rated only two high quality. The most common reason for downgrading evidence was imprecision, with several outcomes being downgraded once, and two were downgraded twice for this reason; this often precluded any meaningful conclusion on the relative benefits of the treatments, as the CIs included significant benefit of both, even if the direction of the estimate favoured one treatment. This imprecision was partly due to the relatively small number of trials that could be included in most of the meta‐analyses, and because some of the outcomes that we considered were rare (serious adverse events and exacerbations requiring hospital admission in particular). </p> <p>Our primary exacerbation outcome, those requiring a course of OCS, was only reported by one study, which made the estimate imprecise. The outcome is also likely to be affected by publication bias, as two studies planned to report time to exacerbation data but omitted the analyses or any related information because "less than 50% of patients in each treatment group experienced an asthma exacerbation" (<a href="./references#CD011438-bbs2-0004" title="NCT01172808 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® Inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 Weeks in moderate persistent asthma. clinicaltrials.gov/show/NCT01172808 (accessed 18 December 2014). ">NCT01172808</a>; <a href="./references#CD011438-bbs2-0005" title="CasaleT , BleeckerE , MeltzerE , PizzichiniE , SchmidtO , BatemanE , et al. Phase III trials to investigate tiotropium as add‐on therapy to inhaled corticosteroids for patients with symptomatic asthma: trial design and planned statistical analyses. Allergy2013;68:377. CasaleTB , BatemanED , DahlR , PizzichiniE , VandewalkerML , VirchowJC , et al. Tiotropium Respimat (R) add‐on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of T(H)2 inflammatory status. Journal of Allergy and Clinical Immunology2014;133(2):Ab5. NCT01172821 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® Inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 Weeks in moderate persistent asthma. clinicaltrials.gov/show/NCT01172821 (accessed 18 December 2014). ">NCT01172821</a>). We learnt through correspondence with the study sponsor that additional data may be available once full manuscripts are published for these trials in 2015. </p> <p>Two studies by the same author team had not been published in peer‐reviewed journals and no data were available on the registration website (<a href="./references#CD011438-bbs2-0003" title="NCT00706446 . Genotype stratified treatment with anticholinergic vs. beta‐agonist (long acting) and exacerbations (GABLE). clinicaltrials.gov/show/NCT00706446 (accessed 18 December 2014). ">NCT00706446</a>; <a href="./references#CD011438-bbs2-0006" title="NCT01290874 . Blacks and exacerbations on LABA vs. tiotropium (BELT). clinicaltrials.gov/show/NCT01290874 (accessed 18 December 2014). ">NCT01290874</a>), which may represent a level of publication bias in all the analyses. It is unclear how these studies may have affected results if they had been completed or reported fully, as the number of randomised participants was not given. <a href="./references#CD011438-bbs2-0007" title="RajanandhMG , NageswariAD , IlangoK . Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxofylline, and tiotropium with budesonide: a randomized controlled study. Clinical Therapeutics2014;36(4):526‐33. ">Rajanandh 2014</a> reported only one outcome that was pre‐specified in this review, percentage predicted FEV<sub>1</sub>, and <a href="./references#CD011438-bbs2-0008" title="IlangoK . A clinical trial to study the effects of few anti asthmatic drug combinations on asthma patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2012/08/002915 (accessed 8 January 2015). RajanandhMG , NageswariAD , IlangoK . Assessment of montelukast, doxofylline, and tiotropium with budesonide for the treatment of asthma: which is the best among the second‐line treatment? A randomized trial. Clinical Therapeutics2015;37(2):41826. RajanandhMG , NageswariAD , IlangoK . Assessment of various second‐line medications in addition to inhaled corticosteroid in asthma patients: a randomized trial. Clinical and Experimental Pharmacology and Physiology2014;41(7):509‐13. ">Rajanandh 2015</a> reported only percentage predicted FEV<sub>1</sub> and SGRQ, and these may have been affected by bias related to their open‐label design; they also could not be combined with the measures reported by other studies in the review, so the evidence was very low quality. </p> <p>Heterogeneity was rarely an issue in the analyses, which may be due to the four studies contributing data to the analyses all being well‐controlled trials that were similar with respect to several of the expected effect moderators (e.g. type of LAMA and LABA compared, background ICS dose, age and study duration). It is for this reason that the applicability of the findings may be compromised. </p> </section> <section id="CD011438-sec-0103"> <h3 class="title" id="CD011438-sec-0103">Potential biases in the review process</h3> <p>We conducted the review to the standards set by <a href="./references#CD011438-bbs2-0060" title="MECIR . Methodological Expectations for the conduct of Cochrane Intervention Reviews. editorial‐unit.cochrane.org/mecir (accessed 3 February 2015). ">MECIR 2013</a>, and in accordance with the published protocol wherever possible (<a href="./references#CD011438-bbs2-0076" title="KewKM , AllisonDE , EvansDJW , BoyterAC . Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long‐acting beta2‐agonists (LABA) for adults with asthma. Cochrane Database of Systematic Reviews2015, Issue 1. [DOI: 10.1002/14651858.CD011438] ">Kew 2015</a>). Any deviations from the protocol have been logged in the <a href="#CD011438-sec-0125">Differences between protocol and review</a> section, and were largely a result of insufficient data as described above. </p> <p>It is unlikely that we missed any relevant studies, as a skilled information specialist conducted the main electronic searches, which were supplemented by extensive supplementary searches of several other resources (drug company trial registries and reference lists of associated studies and reviews), in addition to those required by <a href="./references#CD011438-bbs2-0060" title="MECIR . Methodological Expectations for the conduct of Cochrane Intervention Reviews. editorial‐unit.cochrane.org/mecir (accessed 3 February 2015). ">MECIR 2013</a> (clinicaltrials.gov, WHO trials portal). By searching these additional resources, we identified one study that had been terminated and another that did not reported any data, which illustrates the possibility of publication bias. </p> <p>We also attempted to contact all trial authors for additional or missing data and study information where this was not available in the published reports, and authors of the cross‐over trial provided us with re‐formatted data in a way that accounted for intercorrelation of matched pairs (<a href="./references#CD011438-bbs2-0047" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonH , ValeA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31:140‐9. ">Elbourne 2002</a>). Entering data with these transformations, and entering continuous data using GIV is more accurate for this type of trial, and may explain subtle differences between the results of our review and others. Even so, we tested the robustness of the results by removing the cross‐over data from the primary outcomes in a sensitivity analysis, and conclusions were not affected. </p> </section> <section id="CD011438-sec-0104"> <h3 class="title" id="CD011438-sec-0104">Agreements and disagreements with other studies or reviews</h3> <p>Several systematic reviews have considered the use of tiotropium for asthma compared with a range of possible treatment options (<a href="./references#CD011438-bbs2-0036" title="BefekaduE , OnofreiC , ColiceGL . Tiotropium in asthma: a systematic review. Journal of Asthma and Allergy2014;7:11‐21. ">Befekadu 2014</a>; <a href="./references#CD011438-bbs2-0068" title="RashidQ , KleinR . Tiotropium in the treatment of patients with asthma. Southern Medical Journal2014;107(5):330‐7. ">Rashid 2014</a>; <a href="./references#CD011438-bbs2-0070" title="RodrigoGJ , Castro‐RodríguezJA . What is the role of tiotropium in asthma? A systematic review with meta‐analysis. Chest2015;147(2):388‐96. ">Rodrigo 2015</a>; <a href="./references#CD011438-bbs2-0073" title="TianJW , ChenJW , ChenR , ChenX . Tiotropium versus placebo for inadequately controlled asthma: a meta‐analysis. Respiratory Care2014;59(5):654‐66. ">Tian 2014</a>), some of which considered LABA add‐on as a comparator. </p> <p><a href="./references#CD011438-bbs2-0070" title="RodrigoGJ , Castro‐RodríguezJA . What is the role of tiotropium in asthma? A systematic review with meta‐analysis. Chest2015;147(2):388‐96. ">Rodrigo 2015</a> performed meta‐analyses of several treatment strategies including ICS plus LAMA versus ICS plus LABA and concluded, "the use of tiotropium in patients poorly controlled despite the use of medium to high doses of ICS was not inferior to salmeterol". There were some differences in the meta‐analytic methods used, but the effects were based on the same four studies and showed a broadly similar pattern to the results of this review, with clinically small benefits of tiotropium over LABA on some measures of lung function, small benefits of LABA over tiotropium on the AQLQ, and mostly non‐significant effects on other measures. The authors interpreted this as evidence of non‐inferiority, which may not be justified because there was no pre‐specified margin or necessary conditions to be met to reach this conclusion. </p> <p><a href="./references#CD011438-bbs2-0036" title="BefekaduE , OnofreiC , ColiceGL . Tiotropium in asthma: a systematic review. Journal of Asthma and Allergy2014;7:11‐21. ">Befekadu 2014</a> provided a narrative synthesis of evidence for tiotropium in asthma, referring only to <a href="./references#CD011438-bbs2-0001" title="BatemanED , KornmannO , SchmidtP , PivovarovaA , EngelM , FabbriLM . Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16‐Arg/Arg patients with asthma. Journal of Allergy and Clinical Immunology2011;128(2):315‐22. NCT00350207 . A 16‐week randomised, placebo‐controlled, double‐blind, double‐dummy, parallel‐group study comparing the efficacy and safety of tiotropium inhalation solution delivered by the Respimat Inhaler (2 actuations of 2.5 mcg once daily) with that of salmeterol from the hydrofluoroalkane metered dose inhaler (2 actuations of 25 mcg twice daily) in moderate persistent asthma patients with the B16‐Arg/Arg genotype. clinicaltrials.gov/show/NCT00350207 (accessed 18 December 2014). ">NCT00350207</a> and <a href="./references#CD011438-bbs2-0002" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). clinicaltrials.gov/show/NCT00565266 (accessed 14 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">NCT00565266</a> because the twin trials had not yet been published. Their conclusions were more in line with our own interpretation, highlighting the possible benefits of tiotropium over salmeterol on lung function, which supports further investigation, and acknowledging the inconsistencies and imprecision in study findings overall. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011438-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/urn:x-wiley:14651858:media:CD011438:CD011438-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_t/tCD011438-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011438-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/full#CD011438-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011438-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/urn:x-wiley:14651858:media:CD011438:CD011438-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_t/tCD011438-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011438-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/full#CD011438-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011438-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/urn:x-wiley:14651858:media:CD011438:CD011438-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_t/tCD011438-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting muscarinic antagonists (LAMA) add‐on versus long‐acting beta2‐agonists (LABA) add‐on, Outcome 1 Exacerbations (oral corticosteroid)." data-id="CD011438-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting muscarinic antagonists (LAMA) add‐on versus long‐acting beta<sub>2</sub>‐agonists (LABA) add‐on, Outcome 1 Exacerbations (oral corticosteroid). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/references#CD011438-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011438-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/urn:x-wiley:14651858:media:CD011438:CD011438-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_t/tCD011438-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting muscarinic antagonists (LAMA) add‐on versus long‐acting beta2‐agonists (LABA) add‐on, Outcome 2 Asthma Quality of Life Questionnaire (AQLQ) total." data-id="CD011438-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting muscarinic antagonists (LAMA) add‐on versus long‐acting beta<sub>2</sub>‐agonists (LABA) add‐on, Outcome 2 Asthma Quality of Life Questionnaire (AQLQ) total. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/references#CD011438-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011438-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/urn:x-wiley:14651858:media:CD011438:CD011438-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_t/tCD011438-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting muscarinic antagonists (LAMA) add‐on versus long‐acting beta2‐agonists (LABA) add‐on, Outcome 3 Serious adverse events (all)." data-id="CD011438-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting muscarinic antagonists (LAMA) add‐on versus long‐acting beta<sub>2</sub>‐agonists (LABA) add‐on, Outcome 3 Serious adverse events (all). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/references#CD011438-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011438-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/urn:x-wiley:14651858:media:CD011438:CD011438-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_t/tCD011438-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting muscarinic antagonists (LAMA) add‐on versus long‐acting beta2‐agonists (LABA) add‐on, Outcome 4 Exacerbations (hospital)." data-id="CD011438-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting muscarinic antagonists (LAMA) add‐on versus long‐acting beta<sub>2</sub>‐agonists (LABA) add‐on, Outcome 4 Exacerbations (hospital). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/references#CD011438-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011438-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/urn:x-wiley:14651858:media:CD011438:CD011438-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_t/tCD011438-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting muscarinic antagonists (LAMA) add‐on versus long‐acting beta2‐agonists (LABA) add‐on, Outcome 5 Trough forced expiratory volume in 1 second (FEV1) (L)." data-id="CD011438-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting muscarinic antagonists (LAMA) add‐on versus long‐acting beta<sub>2</sub>‐agonists (LABA) add‐on, Outcome 5 Trough forced expiratory volume in 1 second (FEV<sub>1</sub>) (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/references#CD011438-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011438-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/urn:x-wiley:14651858:media:CD011438:CD011438-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_t/tCD011438-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting muscarinic antagonists (LAMA) add‐on versus long‐acting beta2‐agonists (LABA) add‐on, Outcome 6 Peak FEV1 (L)." data-id="CD011438-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting muscarinic antagonists (LAMA) add‐on versus long‐acting beta<sub>2</sub>‐agonists (LABA) add‐on, Outcome 6 Peak FEV<sub>1</sub> (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/references#CD011438-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011438-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/urn:x-wiley:14651858:media:CD011438:CD011438-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_t/tCD011438-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting muscarinic antagonists (LAMA) add‐on versus long‐acting beta2‐agonists (LABA) add‐on, Outcome 7 Trough peak expiratory flow (PEF) (L/min)." data-id="CD011438-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting muscarinic antagonists (LAMA) add‐on versus long‐acting beta<sub>2</sub>‐agonists (LABA) add‐on, Outcome 7 Trough peak expiratory flow (PEF) (L/min). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/references#CD011438-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011438-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/urn:x-wiley:14651858:media:CD011438:CD011438-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_t/tCD011438-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting muscarinic antagonists (LAMA) add‐on versus long‐acting beta2‐agonists (LABA) add‐on, Outcome 8 Trough forced vital capacity (FVC) (L)." data-id="CD011438-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting muscarinic antagonists (LAMA) add‐on versus long‐acting beta<sub>2</sub>‐agonists (LABA) add‐on, Outcome 8 Trough forced vital capacity (FVC) (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/references#CD011438-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011438-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/urn:x-wiley:14651858:media:CD011438:CD011438-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_t/tCD011438-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting muscarinic antagonists (LAMA) add‐on versus long‐acting beta2‐agonists (LABA) add‐on, Outcome 9 Peak FVC (L)." data-id="CD011438-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting muscarinic antagonists (LAMA) add‐on versus long‐acting beta<sub>2</sub>‐agonists (LABA) add‐on, Outcome 9 Peak FVC (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/references#CD011438-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011438-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/urn:x-wiley:14651858:media:CD011438:CD011438-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_t/tCD011438-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting muscarinic antagonists (LAMA) add‐on versus long‐acting beta2‐agonists (LABA) add‐on, Outcome 10 Asthma Control Questionnaire (ACQ) total." data-id="CD011438-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting muscarinic antagonists (LAMA) add‐on versus long‐acting beta<sub>2</sub>‐agonists (LABA) add‐on, Outcome 10 Asthma Control Questionnaire (ACQ) total. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/references#CD011438-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011438-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/urn:x-wiley:14651858:media:CD011438:CD011438-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_t/tCD011438-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting muscarinic antagonists (LAMA) add‐on versus long‐acting beta2‐agonists (LABA) add‐on, Outcome 11 ACQ response." data-id="CD011438-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting muscarinic antagonists (LAMA) add‐on versus long‐acting beta<sub>2</sub>‐agonists (LABA) add‐on, Outcome 11 ACQ response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/references#CD011438-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011438-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/urn:x-wiley:14651858:media:CD011438:CD011438-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_t/tCD011438-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting muscarinic antagonists (LAMA) add‐on versus long‐acting beta2‐agonists (LABA) add‐on, Outcome 12 Adverse events AEs (all)." data-id="CD011438-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting muscarinic antagonists (LAMA) add‐on versus long‐acting beta<sub>2</sub>‐agonists (LABA) add‐on, Outcome 12 Adverse events AEs (all). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/references#CD011438-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011438-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/urn:x-wiley:14651858:media:CD011438:CD011438-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_t/tCD011438-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting muscarinic antagonists (LAMA) add‐on versus long‐acting beta2‐agonists (LABA) add‐on, Outcome 13 AEs classified as asthma." data-id="CD011438-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting muscarinic antagonists (LAMA) add‐on versus long‐acting beta<sub>2</sub>‐agonists (LABA) add‐on, Outcome 13 AEs classified as asthma. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/references#CD011438-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011438-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/urn:x-wiley:14651858:media:CD011438:CD011438-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_t/tCD011438-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Long‐acting muscarinic antagonists (LAMA) dose subgroups, Outcome 1 Exacerbations (oral corticosteroid)." data-id="CD011438-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Long‐acting muscarinic antagonists (LAMA) dose subgroups, Outcome 1 Exacerbations (oral corticosteroid). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/references#CD011438-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011438-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/urn:x-wiley:14651858:media:CD011438:CD011438-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_t/tCD011438-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Long‐acting muscarinic antagonists (LAMA) dose subgroups, Outcome 2 Asthma Quality of Life Questionnaire (AQLQ) total." data-id="CD011438-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Long‐acting muscarinic antagonists (LAMA) dose subgroups, Outcome 2 Asthma Quality of Life Questionnaire (AQLQ) total. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/references#CD011438-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011438-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/urn:x-wiley:14651858:media:CD011438:CD011438-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_t/tCD011438-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Long‐acting muscarinic antagonists (LAMA) dose subgroups, Outcome 3 Serious adverse events (SAEs) (all)." data-id="CD011438-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Long‐acting muscarinic antagonists (LAMA) dose subgroups, Outcome 3 Serious adverse events (SAEs) (all). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/references#CD011438-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011438-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/urn:x-wiley:14651858:media:CD011438:CD011438-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_t/tCD011438-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Long‐acting muscarinic antagonists (LAMA) dose head‐to‐head, Outcome 1 Exacerbations (oral corticosteroid)." data-id="CD011438-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Long‐acting muscarinic antagonists (LAMA) dose head‐to‐head, Outcome 1 Exacerbations (oral corticosteroid). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/references#CD011438-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011438-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/urn:x-wiley:14651858:media:CD011438:CD011438-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_t/tCD011438-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Long‐acting muscarinic antagonists (LAMA) dose head‐to‐head, Outcome 2 Asthma Quality of Life Questionnaire (AQLQ) total." data-id="CD011438-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Long‐acting muscarinic antagonists (LAMA) dose head‐to‐head, Outcome 2 Asthma Quality of Life Questionnaire (AQLQ) total. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/references#CD011438-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011438-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/urn:x-wiley:14651858:media:CD011438:CD011438-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_t/tCD011438-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Long‐acting muscarinic antagonists (LAMA) dose head‐to‐head, Outcome 3 Serious adverse events (SAEs) (all)." data-id="CD011438-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Long‐acting muscarinic antagonists (LAMA) dose head‐to‐head, Outcome 3 Serious adverse events (SAEs) (all). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/references#CD011438-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011438-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/urn:x-wiley:14651858:media:CD011438:CD011438-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_t/tCD011438-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Sensitivity analysis excluding the cross‐over trial, Outcome 1 Exacerbations (oral corticosteroid)." data-id="CD011438-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Sensitivity analysis excluding the cross‐over trial, Outcome 1 Exacerbations (oral corticosteroid). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/references#CD011438-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011438-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/urn:x-wiley:14651858:media:CD011438:CD011438-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_t/tCD011438-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Sensitivity analysis excluding the cross‐over trial, Outcome 2 Asthma Quality of Life Questionnaire (AQLQ) total." data-id="CD011438-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Sensitivity analysis excluding the cross‐over trial, Outcome 2 Asthma Quality of Life Questionnaire (AQLQ) total. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/references#CD011438-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011438-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/urn:x-wiley:14651858:media:CD011438:CD011438-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_t/tCD011438-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Sensitivity analysis excluding the cross‐over trial, Outcome 3 Serious adverse events (SAEs) (all)." data-id="CD011438-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Sensitivity analysis excluding the cross‐over trial, Outcome 3 Serious adverse events (SAEs) (all). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/references#CD011438-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/media/CDSR/CD011438/image_n/nCD011438-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011438-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Long‐acting muscarinic antagonists (LAMA) add‐on compared with long‐acting beta2‐agonists (LABA) add‐on for adults with asthma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Long‐acting muscarinic antagonists (LAMA) add‐on compared with long‐acting beta<sub>2</sub>‐agonists (LABA) add‐on for adults with asthma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with asthma not well controlled on ICS<br/> <b>Settings:</b> outpatient<br/> <b>Intervention:</b> LAMA add‐on<br/> <b>Comparison:</b> LABA add‐on </p> <p><b>Time point:</b> calculated as the mean duration of the studies contributing to each analysis </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk<sup>3</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>LABA add‐on</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>LAMA add‐on</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbations</b> (OCS) </p> <p>23 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>59 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1000<br/> (30 to 120) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.05</b><br/> (0.50 to 2.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1755<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No clear benefit of 1 add‐on over the other</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AQLQ total</b><br/> 1 = severely impaired; </p> <p>7 = not impaired at all</p> <p>22 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean score in the LABA group was 5.60</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean score in the LAMA group was 0.12 worse<br/> (0.18 worse to 0.05 worse) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1745<br/> (4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small LABA benefit;</p> <p>MCID = 0.5 so difference was unlikely to be clinically significant</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>22 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000<br/> (10 to 42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.84</b><br/> (0.41 to 1.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2012<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low <sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No clear benefit of 1 add‐on over the other</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbations (hospital)</b> </p> <p>22 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/> (1 to 23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.72</b><br/> (0.18 to 2.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2022<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low <sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No clear benefit of 1 add‐on over the other</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trough FEV<sub>1</sub> (L)</b><sup>6</sup> </p> <p>(higher is better)</p> <p>22 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean trough FEV<sub>1</sub> in the LABA group was 0.07 L </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean trough FEV<sub>1</sub> in the LAMA group was 0.05 L better (0.01 better to 0.09 better) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1745<br/> (4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> Moderate <sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small LAMA benefit</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ACQ total</b> </p> <p>0 = no impairment; 6 = maximum impairment</p> <p>23 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean score in the LABA group was 1.31</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean score in the LAMA group was 0.06 higher<br/> (0 higher to 0.12 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1483<br/> (3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small LABA benefit;</p> <p>MCID = 0.5 so difference was unlikely to be clinically significant</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (all)</b> </p> <p>23 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>519 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>544 per 1000<br/> (498 to 592) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.11</b><br/> (0.92 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1839<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>More people on LAMA had an adverse event but the difference with LABA was not statistically significant </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ACQ:</b> Asthma Control Questionnaire; <b>AQLQ:</b> Asthma Quality of Life Questionnaire; <b>CI: c</b> onfidence interval; <b>FEV<sub>1</sub>:</b> forced expiratory volume in 1 second; <b>ICS:</b> inhaled corticosteroid; <b>LABA:</b> long‐acting beta<sub>2</sub>‐agonist; <b>LAMA:</b> long‐acting muscarinic antagonist; <b>MCID:</b> minimal clinically important difference; <b>OCS:</b> oral corticosteroids; <b>OR:</b> odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Confidence intervals include important benefit on either treatment (‐1 imprecision). </p> <p><sup>2</sup> I<sup>2</sup> = 50%, which was not statistically significant (P value = 0.16), but visual inspection of the forest plot showed opposite directions of effect of the pooled twin trials and the cross‐over study (‐1 inconsistency) </p> <p><sup>3</sup> For continuous outcomes, the assumed risk was calculated as a weighted mean of the control group scores (<a href="./references#CD011438-bbs2-0002" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). clinicaltrials.gov/show/NCT00565266 (accessed 14 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">NCT00565266</a> not included in the AQLQ or ACQ calculation because the study reported change from baseline and the remaining studies reported endpoint data). For dichotomous outcomes, it was the pooled control group event rate of all included studies. </p> <p><sup>4</sup> There was some statistical heterogeneity in these outcomes (exacerbations requiring hospital admission: I<sup>2</sup> = 20%, P value = 0.29; trough FEV<sub>1</sub>: I<sup>2</sup> = 46%, P value = 0.14), which was not statistically significant, but visual inspection of the forest plots showed clear variation in study results (‐1 inconsistency). </p> <p><sup>5</sup> Very wide confidence intervals; small number of events in the analysis (‐2 imprecision). </p> <p><sup>6</sup> Other lung function outcomes showed mixed results: small benefit of LAMA on trough PEF (moderate quality), possible but non‐significant benefit of LAMA on peak FEV<sub>1</sub> (very low quality) and trough FVC (moderate quality), no effect on peak FVC (moderate quality), LABA benefit on percentage predicted FEV<sub>1</sub> (very low quality). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Long‐acting muscarinic antagonists (LAMA) add‐on compared with long‐acting beta2‐agonists (LABA) add‐on for adults with asthma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/full#CD011438-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011438-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary characteristics of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total number participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration (weeks)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Design</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ICS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Add‐ons</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean age (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% predicted FEV<sub>1</sub> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011438-bbs2-0001" title="BatemanED , KornmannO , SchmidtP , PivovarovaA , EngelM , FabbriLM . Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16‐Arg/Arg patients with asthma. Journal of Allergy and Clinical Immunology2011;128(2):315‐22. NCT00350207 . A 16‐week randomised, placebo‐controlled, double‐blind, double‐dummy, parallel‐group study comparing the efficacy and safety of tiotropium inhalation solution delivered by the Respimat Inhaler (2 actuations of 2.5 mcg once daily) with that of salmeterol from the hydrofluoroalkane metered dose inhaler (2 actuations of 25 mcg twice daily) in moderate persistent asthma patients with the B16‐Arg/Arg genotype. clinicaltrials.gov/show/NCT00350207 (accessed 18 December 2014). ">NCT00350207</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>International</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P, DB/DD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Budesonide 400‐1000 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Tio Respimat 5 mcg once daily</p> <p>2) Salmeterol 50 mcg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.5</p> <p>42.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.1</p> <p>75.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011438-bbs2-0002" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). clinicaltrials.gov/show/NCT00565266 (accessed 14 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">NCT00565266</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C, DB/DD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Beclomethasone dipropionate 80 mcg x2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Tio HandiHaler 18 mcg once daily</p> <p>2) Salmeterol 50 mcg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011438-bbs2-0003" title="NCT00706446 . Genotype stratified treatment with anticholinergic vs. beta‐agonist (long acting) and exacerbations (GABLE). clinicaltrials.gov/show/NCT00706446 (accessed 18 December 2014). ">NCT00706446</a> </p> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>355**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P, OL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Variable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Tiotropium (dose/ type NR)</p> <p>2) Salmeterol <i>or</i> formoterol (dose NR) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011438-bbs2-0004" title="NCT01172808 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® Inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 Weeks in moderate persistent asthma. clinicaltrials.gov/show/NCT01172808 (accessed 18 December 2014). ">NCT01172808</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>International</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>801</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P, DB/ DD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Continued stable, medium dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Tio Respimat 2.5 mcg once daily</p> <p>2) Tio Respimat 5 mcg once daily</p> <p>3) Salmeterol 50 mcg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.7</p> <p>44.4</p> <p>42.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011438-bbs2-0005" title="CasaleT , BleeckerE , MeltzerE , PizzichiniE , SchmidtO , BatemanE , et al. Phase III trials to investigate tiotropium as add‐on therapy to inhaled corticosteroids for patients with symptomatic asthma: trial design and planned statistical analyses. Allergy2013;68:377. CasaleTB , BatemanED , DahlR , PizzichiniE , VandewalkerML , VirchowJC , et al. Tiotropium Respimat (R) add‐on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of T(H)2 inflammatory status. Journal of Allergy and Clinical Immunology2014;133(2):Ab5. NCT01172821 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® Inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 Weeks in moderate persistent asthma. clinicaltrials.gov/show/NCT01172821 (accessed 18 December 2014). ">NCT01172821</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>International</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>776</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P, DB/DD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Continued stable, medium dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Tio Respimat 2.5 mcg once daily</p> <p>2) Tio Respimat 5 mcg once daily</p> <p>3) Salmeterol 50 mcg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.0</p> <p>44.3</p> <p>41.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011438-bbs2-0006" title="NCT01290874 . Blacks and exacerbations on LABA vs. tiotropium (BELT). clinicaltrials.gov/show/NCT01290874 (accessed 18 December 2014). ">NCT01290874</a> </p> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P, OL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Tio HandiHaler 18 mcg once daily</p> <p>2) Salmeterol 50 mcg <i>or</i> formoterol 12 mcg twice daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011438-bbs2-0007" title="RajanandhMG , NageswariAD , IlangoK . Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxofylline, and tiotropium with budesonide: a randomized controlled study. Clinical Therapeutics2014;36(4):526‐33. ">Rajanandh 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P, OL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Budesonide 400 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Tio HandiHaler 18 mcg once daily</p> <p>2) Formoterol 12 mcg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.4</p> <p>37.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.9</p> <p>66.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011438-bbs2-0008" title="IlangoK . A clinical trial to study the effects of few anti asthmatic drug combinations on asthma patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2012/08/002915 (accessed 8 January 2015). RajanandhMG , NageswariAD , IlangoK . Assessment of montelukast, doxofylline, and tiotropium with budesonide for the treatment of asthma: which is the best among the second‐line treatment? A randomized trial. Clinical Therapeutics2015;37(2):41826. RajanandhMG , NageswariAD , IlangoK . Assessment of various second‐line medications in addition to inhaled corticosteroid in asthma patients: a randomized trial. Clinical and Experimental Pharmacology and Physiology2014;41(7):509‐13. ">Rajanandh 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P, OL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Budesonide 400 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Tio HandiHaler 18 mcg once daily</p> <p>2) Formoterol 12 mcg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.4</p> <p>38.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.1</p> <p>66.2</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>Total number participants is the number randomised to the groups of interest for this review. Age and % predicted FEV<sub>1</sub> are presented as mean values. </p> <p>C: cross‐over; DB/DD: double‐blind, double‐dummy; FEV<sub>1</sub>: forced expiratory volume in 1 second; ICS: inhaled corticosteroids; NR: not reported; OL: open label; P: parallel. </p> <p>* Cross‐over study so characteristics are for the whole population; every participant received each treatment for 14 weeks with a 2‐week washout period. </p> <p>** Planned enrolment and duration ‐ study was terminated.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary characteristics of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/full#CD011438-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011438-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Long‐acting muscarinic antagonists (LAMA) add‐on versus long‐acting beta2‐agonists (LABA) add‐on</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Exacerbations (oral corticosteroid) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.50, 2.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Asthma Quality of Life Questionnaire (AQLQ) total <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.18, ‐0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse events (all) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.41, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Exacerbations (hospital) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.18, 2.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Trough forced expiratory volume in 1 second (FEV<sub>1</sub>) (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.01, 0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Peak FEV<sub>1</sub> (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Trough peak expiratory flow (PEF) (L/min) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.78 [0.86, 10.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Trough forced vital capacity (FVC) (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.02, 0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Peak FVC (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.04, 0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Asthma Control Questionnaire (ACQ) total <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.00, 0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 ACQ response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1563</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.73, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse events AEs (all) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1839</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.92, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 AEs classified as asthma <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1839</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.74, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Long‐acting muscarinic antagonists (LAMA) add‐on versus long‐acting beta2‐agonists (LABA) add‐on</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/references#CD011438-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011438-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Long‐acting muscarinic antagonists (LAMA) dose subgroups</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Exacerbations (oral corticosteroid) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.58, 1.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Respimat 2.5 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.34, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Respimat 5 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.52, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 HandiHaler 18 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [0.65, 4.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Asthma Quality of Life Questionnaire (AQLQ) total <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.18, ‐0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Respimat 2.5 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.1 [‐0.22, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Respimat 5 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.22, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 HandiHaler 18 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.28, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse events (SAEs) (all) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.46, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Respimat 2.5 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.36, 2.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Respimat 5 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.25, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 HandiHaler 18 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.20, 5.09]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Long‐acting muscarinic antagonists (LAMA) dose subgroups</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/references#CD011438-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011438-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Long‐acting muscarinic antagonists (LAMA) dose head‐to‐head</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Exacerbations (oral corticosteroid) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.40, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Asthma Quality of Life Questionnaire (AQLQ) total <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.09, 0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse events (SAEs) (all) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.47, 2.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Long‐acting muscarinic antagonists (LAMA) dose head‐to‐head</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/references#CD011438-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011438-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Sensitivity analysis excluding the cross‐over trial</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Exacerbations (oral corticosteroid) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Asthma Quality of Life Questionnaire (AQLQ) total <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.19, ‐0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse events (SAEs) (all) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1839</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.30, 2.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Sensitivity analysis excluding the cross‐over trial</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011438.pub2/references#CD011438-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011438.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD011438-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD011438-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011438-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011438-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD011438-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ru#CD011438-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011438-note-0006">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011438\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011438\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011438\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011438\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011438\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011438\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011438\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011438\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011438\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011438\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011438\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011438\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011438\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011438\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011438\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011438\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011438\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011438\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=VXKc2U6b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011438.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011438.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011438.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011438.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011438.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716336516"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011438.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716336520"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011438.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d9d08aa979368',t:'MTc0MDcxNjMzNi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 